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DEVELOPMENT OF GLUCOCOTICOID PRODRRUG FOR THE
TREATMENT OF LUPUS NEPHRITIS
Xiaobei Wang, Ph.D candidate
University of Nebraska Medical Center, 2018
Supervisor: Dong Wang, Ph.D.
Nephritis is one of the major complications of systemic lupus erythematosus
(SLE). While glucocorticoids (GC) are frequently used as the first line treatment
for lupus nephritis, long-term GC usage is often complicated by severe adverse
effects. To address this challenge, we have developed a polyethylene glycol
(PEG)-based macromolecular prodrug (ZSJ-0228) of dexamethasone, which selfassembles into micelles in aqueous media.

When compared to the dose

equivalent daily dexamethasone 21-phosphate disodium (Dex) treatment,
monthly intravenous administration of ZSJ-0228 for two months significantly
improved the survival of lupus-prone NZB/W F1 mice and was much more
effective in normalizing proteinuria, with clear histological evidence of nephritis
resolution. Different from the dose equivalent daily Dex treatment, monthly ZSJ0228 administration has no impact on the serum anti-double-stranded DNA (antidsDNA) antibody level but can significantly reduce renal immune complex
deposition. No significant systemic toxicities of GC (e.g. total IgG reduction,
adrenal gland atrophy and osteopenia, etc.) were found to associate with ZSJ0228 treatment. In vivo imaging, flow cytometry and pharmacokinetic studies
reveal that the fluorescent or

125

I-labeled ZSJ-0228 primarily distributes to the
v

inflamed kidney after systemic administration, with renal myeloid cells and
proximal tubular epithelial cells mainly responsible for its kidney retention.
Collectively,

these

data

suggest

that

the

potent

local

anti-

inflammatory/immunosuppressive effects and improved safety of ZSJ-0228 may
be attributed to its tropism and cellular sequestration in the kidney. Pending
further optimization, ZSJ-0228 may be developed into an effective and safe
therapy for improved clinical management of lupus nephritis.
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CHAPTER I. CURRENT TREATMENT OF LUPUS NEPHRITIS

1.1 Introduction

Systemic lupus erythematosus (SLE) is a severe chronic autoimmune disease
with no cure. The hallmark of SLE is the presence of anti-double-stranded (ds)
DNA antibodies depositing on the basement membranes of organs and tissues,
including; kidney, joint, skin, pericardium, brain, lung and blood vessels. The
prevalence of SLE is increasing, probably due to the identification of milder cases
and improved survival rate. In the United States, approximately 1.5 million people
are SLE sufferers.[1] According to the American College of Rheumatology, 90%
of SLE patients are women of childbearing age.[2] People of African, Hispanic, or
Asian tend to have a raised prevalence of lupus.[3] Findings from the Euro-lupus
project-a prospective cohort study of 1000 patients with lupus followed up from
1991-showed significantly higher risk of lupus nephritis and a greater mortality
rate in children than in patients who develop the disease as adults.[4]

Lupus nephritis is one of the most serious complications of SLE. It can be
defined by the clinical picture, together with the inflammatory damage to nephrons
in the context of SLE. The disease is initiated by immune complex deposition on
the basement membranes of glomeruli, which triggers immune events including;
activation of complement[5], binding of Fc receptors on neutrophils and
1

macrophages,[6] recruitment of inflammatory cells, and finally fibrosis. Lupus
nephritis contributes directly to morbidity and mortality of SLE patients due to
difficulty in the early recognition of renal disease and its poor prognosis. Only 25
to 50% of lupus patients show proteinuria or other abnormalities of renal function
in the early course, although up to 60% of adults and 80% of children may develop
overt renal disease later.[7] In the United States, lupus nephritis affects 30% of
adults and 70% of children with SLE. Lupus nephritis is a major cause of endstage renal disease (ESRD),[8] and the incidence of ESRD in SLE is increasing
in the USA.[9, 10]

1.2 Pathogenesis of Lupus Nephritis

The pathogenesis of lupus is multifaceted and encompasses deregulation
in adaptive as well as innate immune responses.[11-14]

Immune complex

accumulation in the kidney is the hallmark of lupus nephritis and triggers a series
of events that results in kidney inflammation and injury. Numerous hypotheses
have been proposed to explain the mechanism of glomerular immune complex
accumulation, including the deposition of immune complexes from the circulating
blood,[6] and the circulating nephritogenic antichromatin antibodies recognizing
the glomerular basement membrane-associated chromatin fragments derived
from apoptotic intraglomerular cells.[15] The latter hypothesis has been validated
by recent reports for both murine[15, 16] and human lupus nephritis.[17-21]
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Lupus nephritis is a highly heterogeneous disease which can be driven by
different pathogenic mechanisms. It is initiated by the immune complex deposition
on the glomerular basement membrane which triggers a cascade of inflammatory
mediators

activation

(including

Fc

receptors[6]

and

complement[22]),

inflammatory cell recruitment and eventual renal fibrosis. As the disease
progresses, both innate and acquired immune pathways will be activated and
cross-react to create interacting networks which makes it increasingly difficult to
regulate.[23]

Intrarenal immune complexes, especially those involving IgG1 and IgG3
autoantibodies, can activate complement and recruit leukocytes to nephritic
kidneys via the complement C3a and C5a, resulting in complement-mediated
kidney damage observed in both murine and human lupus nephritis.[24-31] The
recruited leucocytes and residential kidney cells both produce proinflammatory
cytokines and chemokines in response to immune complexes and complement
fragments. A typical example is the Increased serum IFN- levels observed in
lupus patients.[32] In lupus nephritis, circulating plasmacytoid dendritic cells
(pDCs) accumulate in the kidneys and increase the renal levels of IFN- upon
activation by renal immune complexes.[33, 34] The IFN- serum levels correlate
with lupus activity and signs of immune activation.[35]

IFN- induces the

maturation of conventional dendritic cells into potent antigen-presenting cells

3

(APC),[36] facilitates B-cell activation,[37] and promotes the development of CD4+
T helper cells (TH cells)[38] and CD8+ memory T cells.[39] Recent work has
uncovered aberrant expansion and dysregulation of several T H effector subsets,
including TH-17 and TH-1 cells, in lupus.[40-43] One of the critical mechanisms
by which these effector TH subsets contribute to lupus is via the production of
cytokines, including IL-12, IL-21, and IFN-.[44-46] Aberrant activation of innate
immune cells such as dendritic cells, macrophages, and neutrophils has also
been associated with lupus pathogenesis.[47-51] Neutrophils and macrophages
are recruited to the inflamed kidney and cause the direct renal injury through
secreting proteolytic enzymes and oxygen radicals. Neutrophil debris may further
contribute to lupus nephritis via releasing neutrophil extracellular traps (NETs),
which can bind to the antichromatin autoantibodies [52-54]. Moreover, NETs can
promote pDCs secretion of IFN- [52], thereby amplifying the autoimmune
activity.

In addition to circulating autoantibodies, immune complexes can also be
produced within the renal parenchyma, where T and B cells aggregate and form
ectopic lymphoid tissue, in the tubulointerstitial compartment [55, 56]. Interstitial
plasma cells within the ectopic lymphoid tissue can produce autoantibodies in a
clonally restricted fashion [57, 58], which may be an explanation for kidneyspecific autoimmunity, and has been confirmed in a recent report showing that
interstitial

nephritis

occurs

in

the

complete

absence

of

circulating

4

immunoglobulins in a murine lupus model [59]. Similarly, human pauci-immune
nephritis has been observed in the lupus patients [60].

Collectively, the pathogenesis of lupus nephritis can be summarized as an
inflammatory response to immune complexes in the kidneys. A cascade of
inflammatory events, including complement activation, leukocyte infiltration,
cytokine

release

from

leukocytes

and

intrinsic

kidney

cells,

renal

parenchymalinjury and renal fibrosis amplify the renal inflammation via a series of
positive-feedback loops. Inflammatory injury in kidneys results in the apoptosis
and necrosis of intrinsic kidney cells, which is the source of the autoantigens.
These autoantigens may cause intrarenal production of kidney-specific
autoantibodies in the presence of infiltrated APCs, T cells, IFN- and other
cytokines. Therefore, treatment regimen should focus on firstly diminishing
inflammation in active lupus nephritis to preserve renal parenchyma, followed by
suppressing kidney-specific autoimmunity to prevent the reactivation of lupus
nephritis.

1.3 Anti-inflammatory Therapies

As lupus nephritis is a severe manifestation of SLE, usually accompanied by
end-stage kidney disease or renal replacement challenges, glucocorticoids plus
an immunosuppressive has been the standard therapy for severe lupus nephritis.
5

Since the 1980s, some novel biologics or small molecules were found useful in
the inflammation control.

Glucocorticoids (GCs). Among these treatment options, GC is one of the most
potent and widely used drugs for lupus. It is naturally produced by the adrenal
gland and its therapeutic effect is activated through binding to GC receptor (GR).
In American College of Rheumatology (ACR)’s new guidelines for clinical
management of lupus nephritis [2], the recommended treatment regimen consists
of a pulse GC treatment followed by low/high-dose daily GC plus an
immunosuppressive medication. Compared to the previous guidelines [61], the
major change is that new immunosuppressants (e.g. mycophenolate mofetil) have
been added as alternatives to cyclophosphamide due to concerns regarding the
adverse effects of this immunosuppressive agent including; leukopenia, alopecia,
vulnerability to infections, gonadal toxicity, haemorrhagic cystitis, uroepithelial
tumors and an increased incidence of other malignancies [62]. However, no
alternatives have been recommended for GC. The ACR guidelines recommend
treatment with three pulses of intravenous methylprednisolone for all lupus
nephritis patients [2]. In current clinical practice, oral prednisone or prednisolone
is generally commenced at a dose of 0.7–1.0 mg/kg body weight daily, and
reduced by 2.5–5.0 mg every 2 weeks until the long-term maintenance dose of
5.0–7.5 mg daily is achieved [62].

6

Laquinimod.

Laquinimod is a small molecular derivative of quinolone-3-

carboxamide. It has been investigated as an oral therapy for multiple sclerosis
(MS) in two Phase II trials, and has completed a Phase II trial in lupus nephritis
(clinical trial NCT01085097 at www.clinicaltrials.gov). Laquinimod seems to be
able to reduce MS activity as an anti-inflammatory agent through decreasing the
infiltration of monocytes into the central nervous system (CNS), and reducing
proinflammatory cytokine and transcription factor expression, such as monocyte
protein 1 (MCP-1) and nuclear factor-B (NF-B) [63, 64]. Suppression of
inflammatory cytokine and chemokine genes and lower expression of NF-B has
been observed in the leukocytes and dendritic cells of healthy or MS patients
treated with laquinimod. Even though Phase III studies for MS (clinical trial
NCT00509145 at www.clinicaltrials.gov) have been shown to not significantly
reduce relapses in MS among patients beyond a placebo, it proved oral
administered once daily with laquinimod slowed the progression of disability and
decreased the relapse rate in patients with relapsing-remitting MS [65].

Tocilizumab and Sirukumab (Anti-IL-6).

IL-6 is a multifunctional cytokine

produced by leukocytes as well as residential kidney cells that contributes to
autoimmunity by stimulating B-cell differentiation and maturation, CD8 + T-cell
differentiation, autoantibody secretion, and renal mesangial cell proliferation [6668]. Accumulating evidence supports a pivotal role of IL-6 in murine and human
lupus nephritis. NZB/W F1 mice administered recombinant human IL-6
demonstrated an accelerated and severe form of membranoproliferative
7

glomerulonephritis [66, 69]. While administration of anti-IL-6 receptor antibody
significantly attenuated proteinuria and prolonged the lifespan of NZB/W lupus
mice, with only one out of ten dying from severe proteinuria [70]. IL-6 levels were
increased in serum, urine, and glomeruli of mice and humans with SLE, and
correlated with autoimmune activity [71, 72].

Toculizumab is a humanized

monoclonal anti-IL-6 antibody (clinical trial NCT00046774, www.clinicaltrials.gov).
A Phase I clinical trial in lupus patients evaluated the safety and efficacy of
toculizumab. Sirukumab, another humanized monoclonal antibody against IL-6,
is presently undergoing a Phase II clinical trial to demonstrate its safety and
tolerability in lupus nephritis (clinical trial NCT01273389, www.clinicaltrials.gov).
However, due to the multi-functional attributes of IL-6in inflammation, cell
proliferation, and autoimmunity, it is difficult to determine therapeutic targets in
the proper treatment phase, which may arise the inflammatory disorder if
improperly used.

Eculizumab (Anti-C5). Eculizumab is a fully humanized recombinant IgG2/IgG4
monoclonal antibody against human complement fragment C5. It blocks the
conversion of C5 to C5a and C5b, thereby preventing formation of the membrane
attack complex (C5b-9) and the chemotactic fragment C5a. Although eculizumab
is only approved for the treatment of paroxysmal nocturnal hemoglobinuria and
atypical hemolytic uremic syndrome [73], it is conceivable that eculizumab could
prevent direct complement-mediated injury to residential glomerular cells and
reduce renal inflammation via diminishing renal leukocyte infiltration in lupus
8

nephritis. So far, it has been shown to be safe and tolerated in a Phase I trial in
SLE [74].

1.4 Anti-autoimmunity Therapies

Rontalizumab and Sifalimumab (Anti-IFN-). Rontalizumab and sifalimumab
are humanized antibodies against IFN-. Given IFN-'s critical roles in dendritic
cell maturation, B-cell activation and T-cell development, it is a good strategy to
neutralize the activity of IFN- to prevent further disease flares. In a recent study
of endogenous anti-IFN- autoantibodies decreasing the IFN- levels and SLE
activity, 22% of 49 SLE patients were found to have naturally produced anti-IFN autoantibodies and a lower IFN- gene signature than patients without such
antibodies [75]. Patients with higher levels of anti-IFN- autoantibodies and lower
IFN- gene signature were inclined to have less positive lupus serologic test
results, lower SLEDAI (Systemic Lupus Erythematosus Disease Activity Index)
score, and higher complement levels. Additionally, ~35% of these SLE patients
with low IFN- gene signature did not have anti-IFN- autoantibodies, indicating
that exogenous anti-IFN- therapy might not benefit all patients. The safety and
efficacy of rontalizumab and sifalimumab has been tested in three small Phase I
studies with SLE patients having only mild or moderate disease [76-78]. In general,
rontalizumab and sifalimumab inhibited the gene signature in a dose-dependent
manner. However, the inhibitory effect was short lived and did not completely
9

reverse the expression of IFN- genes. In the clinical trial of rontalizumab, neither
the protein levels of IFN- genes nor the levels of anti-IFN- autoantibodies was
decreased after therapy [76].

Belimumab (Anti-BLyS/BAFF). The B lymphocyte stimulator (BLyS, also termed
BAFF) family is essential for B-cell development, selection and homeostasis. Mice
genetically knocked out of BLys show the deficiency of mature B cells and
immunoglobulin levels [79]. In contrast, overexpression of BLyS observed in
transgenic mice and human SLE results in B-cell expansion and autoimmunity
[80-82]. Belimumab, a fully humanized monoclonal anti-BLyS/BAFF antibody,
can cause depletion of circulating B cells. Preliminary results from a Phase III
study in SLE patients without lupus nephritis have demonstrated depleted
peripheral B cells within 3-6 months with limited effects on memory B cells and
plasmablasts. Patients who received belimumab plus standard care have shown
an improved clinical manifestation, including prevention of disease flares
compared to the placebo group over 52 weeks [83]. However, whether chronic
B-cell depletion caused by the belimumab treatment will induce homeostatic
expansion of autoreactive memory B cells and whether belimumab has an effect
on B-cell selection over time needs to be further determined.

Cyclophosphamide and Mycophenolate Mofetil. Both of cyclophosphamide
and mycophenolate mofetil are used as immunosuppression reagents targeting

10

activated lymphocytes. Glucocorticoids plus cyclophosphamide as standard
induction therapy for severe proliferative lupus nephritis was recommended by
the ACR guidelines published in 1999 [61]. However, outcomes after broadspectrum immunosuppressive therapy remain unsatisfactory. In a comparison
trial, cyclophosphamide and mycophenolate mofetil were equivalent in the
induction of remission of lupus nephritis, with complete remission rates of 50%
[84]. Clinical trials indicated combined treatment with cyclophosphamide and
glucocorticoids correlated with an increased incidence of adverse effects and
significantly higher mortality (18.2%, versus 3.7% in patients treated with
glucocorticoids alone) when compared to glucocorticoids alone [85-87], even
though the combined therapy was more effective in maintaining disease
quiescence and improving renal outcomes [85, 86, 88]. Given the accumulating
concerns regarding the adverse effects of cyclophosphamide, novel therapies are
being investigated to decrease cyclophosphamide exposure.

Mycophenolate

mofetil is a selective, reversible and noncompetitive inhibitor of lymphocyte
proliferation and has been used in the prevention of renal allograft rejection, as
well as in the therapy of glomerular disorders. The greater efficacy and reduced
incidence of adverse effects including infections make mycophenolate mofetil an
attractive candidate to in the treatment of lupus nephritis [89, 90]. However,
mycophenolate mofetil cannot replace the combined administration of
cyclophosphamide with glucocorticoids in the treatment of severe lupus nephritis
[91].

11

Rituximab (B-cell directed therapies).

Rituximab is a humanized/mouse

chimeric monoclonal antibody against CD20, a cell surface molecule present on
most B cells but not plasma cells. The rationale for Rituximab treatment on lupus
nephritis is depletion of autoreactive B cells. While rituximab is B-cell selective,
two large clinical trials, LUNAR (Lupus Nephritis Assessment with Rituximab) and
EXPLORER (Exploratory Phase II/III SLE Evaluation of Rituximab), failed due to
lack of efficacy on SLE and lupus nephritis when combined with standard-of-care
treatment [92, 93]. The reasons for the failure is still debated, however, there are
some caveats to rituximab treatment should be considered. Because plasma
cells do not express CD20, rituximab does not cause an immediate elimination in
autoantibody levels, which might be one of the reasons for failure. Yet, a decline
of the existing autoreactive plasma cells will occur resulting from the B-cell
depletion. Furthermore, rituximab may even promote autoreactive B cells.
BLyS/BAFF levels increase as B cells are depleted in response to rituximab
treatment [94, 95], which may elevate the production of new autoreactive B cells.

Abatacept (T-cell directed therapies). CD28:B7 costimulatory interaction, the
most critical signal driving T-cell activation, can be blocked via CTLA4 binding to
B7 on the surface of dendritic cells or B cells. Abatacept, a fusion protein between
CTLA4 and IgG heavy chain components, can interfere CTLA4:B7 binding so as
to inhibit T-cell activation.

Abatacept has been tested in two randomized

controlled trials in lupus nephritis as a combinational therapy to either low-dose
cyclophosphamide (ACCESS [Abatacept and Cyclophosphamide Combination
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Therapy

for

Lupus

www.clinicaltrials.gov)
www.clinicaltrials.gov).

Nephritis]
or

Trial,

MMF

clinical

(clinical

trial
trial

NCT00774852,
NCT01714817,

Murine studies showed that abatacept plus low-dose

cyclophosphamide induced complete lupus nephritis remission [96, 97]. However,
abatacept did not improve complete renal response rates in either clinical trial [98].

1.5 Summary

In recent years, more novel bioagents were developed to treat lupus
nephritis, one of the most severe complicates of SLE and can drive a high
mortality rate if improper treated. However, none of them showed enhanced
efficacy and meanwhile showing less toxicity. The optimal treatment approach of
lupus nephritis is to suppress the acute inflammation to maintain the renal
parenchyma followed by the anti-autoimmune therapy to prevent the subsequent
renal injury caused by the infiltrated inflammatory cells. Amongst all the antiinflammatory, GC is one of the most potent and widely used drugs for lupus. A
pulse

GC

treatment

followed

by

low/high-dose

daily

GC

plus

an

immunosuppressive medication is still the standard-care recommended by
American College of Rheumatology (ACR)’s new guidelines for clinical
management of lupus nephritis. Recently, mycophenolate mofetil is suggested to
be used as alternative to cyclophosphamide for its higher tolerance in the lupus
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patient. No alternatives have been recommended for GC, especially for the
serious lupus nephritis treatment.

As a hydrophobic small molecular drug, GC can disperse into multiple
systems (including nervous, cardiovascular, musculoskeletal, endocrine systems),
resulting in the notorious GC-associated side effects. These adverse side effects
contribute significantly to morbidity in lupus patients.

Therefore, it needs to be

careful to use GC in the long-term management. The actions of GC are mediated
through two distinct pathways: transactivation and transrepression, which are
postulated to be related to GC-associated side effects and anti-inflammatory
effects, respectively. Even though some GC receptor agonists can activate the
transrepression pathway to treat inflammation, it is inevitable to trigger the
transactivation responsible for the GC-related side effects due to the poor
selectivity. Herein, instead of using GC receptor agonists, modifying GC’s PK/BD
profile in organs might be a wise strategy for the lupus nephritis treatment.

Nanomedicine is a growing area of research. Rather than looking for new
molecular targets in autoimmune disease, nanomedicine-based drug delivery
system is designed at enhancing the tissue selectivity by altering its
pharmacokinetics and biodistribution. In the previous study, we conjugated
dexamethasone to a water-soluble N-(2-hydroxypropyl)-methacrylamide (HPMA)
copolymer via an acid-labile hydrazone linker to obtain a macromolecular prodrug
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of Dex (P-Dex). The enhancing therapeutic efficacy of P-Dex was achieved
compared to dexamethasone treatment. However, a relatively high accumulation
of P-Dex in liver and other GC-related side effects such as adrenal gland atrophy
and WBC reduction still existed. In this thesis, we have developed a novel PEGbased prodrug that can target dexamethasone to nephritic kidney, retain the
potent efficacy and reduce the GC-associated side effects. The hypotheses to be
tested are: (1) A novel PEG-based dexamethasone prodrug was synthesized and
the micellar structure will be determined. (2) When tested in lupus nephritis animal
models,

the

PEG-Dex

demonstrates

potent

efficacy

with

significantly

reduced/abolished side effects; and, (3) The mechanism of the superior efficacy
and safety of PEG-Dex compared to Dex is elucidated via pharmacokinetics
studies.
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CHAPTER II
SYNTHESIS AND CHARACTERIZATION OF PEG-BASED
DEXAMETHASONE PRODRUG

2.1 Introduction

Glucocorticoid is one of the oldest synthetic drugs in the modern medicine.
It was purified from the adrenal gland by Edward C. Kendall in the 1930s. Since
then, the synthesis of these chemical compounds in large quantities became
possible, resulting in the first application of cortisone in the treatment of
rheumatoid arthritis (RA) [99]. Furthermore, the administration routes of
glucocorticoids have been developed, including oral; intravenous, topical and
phosphate derivatives applied to enhance the solubility in aqueous solution [100].

A treat-to-target (T2T) strategy including a number of fundamental
principles in the SLE management was recently recommended and published by
a European panel [101]. Briefly, lupus treatment should achieve the goals of; longterm survival, prevention of organ damage, optimization of life quality by adequate
disease activity control, reduction of comorbidities, and treatment-induced side
effects. Although the prognosis can be dramatically improved by lupus nephritis
management, the treatment is potentially toxic, complex, prolonged and difficult
16

to plan and carry out. A typical example is the use of glucocorticoids and
cyclophosphamide as induction therapy for proliferative lupus nephritis
recommended by the ACR guidelines published in 1999 [61]. It might be a
superior therapeutic approach in particular populations, such as AfricanAmericans, however, it is also potential to induce a high infection risk and organassociated adverse effects. Due to the fact that the activated targets of these
therapeutic agents in vivo are ubiquitously distributed throughout the body, the
systemic administration may result in the activation of these drugs in undesired
sites which brings up the toxicities. Hence, the question of how to develop a novel
drug delivery system of glucocorticoids which can target the drugs to inflamed
kidney(s) become the major challenges in modern medicine. To help address
these hurdles, this section will offer a brief but broad overview in the current
research of novel nanomedicine-based drug delivery system of glucocorticoids.

2.2 Materials & Methods

2.2.1 Materials & Instruments

Dexamethasone was obtained from Tianjin Pharmaceuticals Group Co., Ltd.
(Tianjin, China). Dexamethasone 21-phosphate disodium (Dex) was purchased
from Hawkins, Inc. (Minneapolis, MN, USA).

Heterofunctional PEGs were

purchased from Rapp Polymere GmbH (Tuebingen, Germany) and Creative
17

PEGWorks (Chapel Hill, NC, USA).

Piperidine was purchased from Sigma-

Aldrich (St. Louis, MO, USA). Sephadex LH-20 resins were purchased from GE
HealthCare (Piscataway, NJ, USA). IRDye 800CW NHS ester was purchased
from LI-COR Biosciences (Lincoln, NE, USA). Alexa Fluor 488 NHS ester was
obtained from Life Technologies (Carlsbad, CA, USA).

1

H and
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C NMR spectra were recorded on a 500 MHz NMR spectrometer

(Varian, Palo Alto, CA, USA). The mass spectrum analyses were performed with
an LC/MS/MS system composed of an ACQUITY Ultra Performance LC (UPLC)
system (Waters, Milford, MA, USA) and a mass spectrometer of Sciex 4000 Q
TRAP with an ESI source (Applied Biosystems, Toronto, Canada).

HPLC

analyses were performed on an Agilent 1100 HPLC system (Agilent Technologies,
Inc., Santa Clara, CA, USA) with a reverse phase C 18 column (Phenomenex,
Bondclone H16-441537-C18, 300×3.9 mm, 10 µm). The average hydrodynamic
diameter, polydispersity index (PDI) and zeta potential of micelles were
determined by dynamic light scattering (DLS) experiments using a Zetasizer Nano
ZS90 (Malvern Instruments, Worcestershire, UK). The particle size distribution
was analyzed using NS300 NanoSight (Malvern Instrument).

The micelles

morphology was observed using a Tecnai G2 Spirit transmission electron
microscope (TEM) (FEI, Hillsboro, OR, USA) at an acceleration voltage of 100 kV.

2.2.2 The synthesis of ZSJ-0228 (Scheme 2)
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The synthesis of compound 1. Imidazole (2.72 g, 40 mmol) and dexamethasone
(7.84 g, 20 mmol) were dissolved in anhydrous N,N-dimethylformamide (DMF, 40
mL). After the solution was cooled to 0°C, tert-butyldimethylsilyl chloride (TBSCl,
3.3 g, 22 mmol) was added. The solution was maintained at 0°C for 3 hours and
room temperature for 2 hours, with constant stirring. Ethyl acetate (100 mL) was
then added and washed with brine (80 mL4). The organic phase was separated
and dried over MgSO4. After removal of the solvent, the residue was purified with
flash chromatography (ethyl acetate:hexane = 1:2) to produce compound 1 (9.98
g). Yield: 98.5%.
H NMR (500 MHz, DMSO-d6): δ (ppm) = 7.28 (d, J = 10.2 Hz, 1H), 6.22 (d, J =

1

10.2 Hz, 1H), 6.00 (s, 1H), 5.29 (s, 1H), 4.97 (s, 1H), 4.78 (d, J 2.61 (td, J = 13.6
Hz, 5.8 Hz, 1H), 2.36 (m, 2H), 2.11 (m, 2H), 1.76 (m, 1H), 1.62 (q, J = 11.8 Hz,
1H), 1.48 (s, 3H), 1.41 (d, J = 13.5 Hz, 1H), 1.33 (m, 1H), 1.06 (m, 1H), 0.88 (s,
9H), 0.87 (s, 3H), 0.77 (d, J = 7.2 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H).
C NMR (125 MHz, DMSO-d6): δ (ppm) = 209.19, 185.45, 167.20, 152.94,
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129.17, 124.29, 101.38 (d, JC-F = 174 Hz), 90.52, 70.84 (d, JC-F = 36.9 Hz), 68.14,
48.13 (d, JC-F = 22.5 Hz), 47.65, 36.03, 35.33, 33.82 (d, J C-F = 19.3 Hz), 32.09,
30.46, 27.42, 25.97, 23.11, 23.08, 18.34, 16.86, 15.38, -4.89, -5.04.
MS (ESI): m/z = 507.2 (M + H+), calculated 506.3.
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Synthesis of compound 2.

NH2NH2 monohydrate (750 mg, 15 mmol) and

compound 1 (2.53 g, 5 mmol) from the first step were dissolved in methanol (25
mL). After addition of acetic acid (60 mg, 1 mmol), the solution was stirred at
room temperature for 5 hours. Ethyl acetate (100 mL) was then added and the
solution was washed with brine (80 mL4). The organic phase was separated
and dried over MgSO4. After solvent removal with rotary evaporation, the residue
was purified with flash chromatography (ethyl acetate:hexane = 1:1) to produce
compound 2 (1.14 g). Considering the recovery of unreacted compound 1 (1.24
g), we calculate the final yield at 85.8%.

Because of the hydrazone bond

formation, a mixture of two syn/anti configure isomers exist in the product. But
they are indistinguishable on flash chromatography. The two isomers’ molar ratio
was determined to be 1.63:1 according to 1H-NMR.

H NMR (500 MHz, DMSO-d6): δ (ppm) = 6.67 (d, J = 10.4 Hz, 0.38H), 6.39 (s,

1

0.62H), 6.28 (d, J = 10.4Hz, 0.38H), 6.23 (s, 2H), 6.03 (d, J = 11.5Hz, 0.62H),
5.98 (d, J = 11.5Hz, 0.62H), 5.76 (s, 0.38H), 5.09 (dd, J = 10.5Hz, 3.0Hz, 1H),
4.96 (s, 1H), 4.74 (d, J = 19.1Hz, 1H), 4.26 ( d, J = 19.1Hz, 1H), 4.09 (m, 1H),
2.87 (m, 1H), 2.50 (m, 1H), 2.22 (m, 1H), 2.16 (m, 3H), 1.58 (m, 2H), 1.36 (s, 3H),
1.33 (d, J = 13.5 Hz, 1H), 1.26 (m, 1H), 1.02 (m, 1H), 0.85 (s, 9H), 0.81 (s, 3H),
0.74 (d, J = 7.2 Hz, 3H), 0.02 (s, 3H), 0.01 (s, 3H).
C NMR (125 MHz, DMSO-d6): δ (ppm) = 209.71, 170.98, 151.16, 144.73,
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140.74, 140.62, 139.03, 132.91, 127.70, 121.61, 116.17, 110.81, 100.71 (d, J C-F
= 171.9 Hz), 100.50 (d, JC-F = 171.9 Hz), 90.92, 90.87, 70.00 (d, JC-F = 37.4 Hz),
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69.93 (d, JC-F = 37.3 Hz), 68.43, 60.29, 47.21 (d, JC-F = 22.8 Hz), 47.05 (d, JC-F =
22.8 Hz), 44.02, 36.41, 36.35, 35.62, 34.40 (d, JC-F = 19.5 Hz), 34.36 (d, JC-F =
19.5 Hz), 25.28, 25.24, 24.85, 24.82, 21.17, 18.58, 17.15, 15.63, 14.49, -4.67, 4.80.
MS (ESI): m/z = 521.5 (M + H+), calculated: 520.3.
LC/MS: two peaks in the chromatography with the retention time at 5.74 min and
6.32 min were found with the same molecular weight at 521.356 (condition: A: 7.5
mM ammonium acetate; B: 95% MeOH and 5% Acetonitrile; A:B = 30:70).

Synthesis of compound 3. 4-Dimethylaminopyridine (DMAP, 201 mg, 1.65 mmol)
and compound 2 (2.86 g, 5.5 mmol) were dissolved in anhydrous DMF (15 mL).
After

cooling

to

0°C,

Fmoc-glycine

(2.12

g,

7.15

mmol)

and

dicyclohexylcarbodiimide (DCC, 1.70 g, 8.25 mmol) were added. The resulting
solution was stirred at 0°C for 3 hours. Ethyl acetate (100 mL) was then added,
and the solution was washed with brine (80 mL4). The organic phase was
separated and dried over MgSO4. After removal of the solvent, the residue was
purified by flash chromatography (ethyl acetate/hexanes=1:1) to produce crude
compound 3 (3.72 g). The yield is 84.5%. TLC indicates the presence of small
amount of side products, which were difficult to separate. The crude product was
used directly in the next reaction.
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Synthesis of compound 4. Compound 3 (3.0 g, 3.75 mmol) was dissolved in
dichloromethane (DCM, 10 mL) and then cooled to 0°C.

After addition of

piperidine (1 mL), the solution was stirred at 0°C for 3 hours. Ethyl acetate (100
mL) was then added and washed with brine (80 mL3). The organic phase was
separated and dried over MgSO4. After removal of the solvent, toluene (50 mL)
was added and then evaporated to help remove the residue piperidine. After
purification with flash chromatography (ethyl acetate followed by ethyl
acetate:methanol = 2:1), 1.96 g of compound 4 was produced. The yield is
calculated as 90.6%.

H NMR (500 MHz, DMSO-d6): δ (ppm) = 7.01 (d, J = 10.3Hz, 0.23H), 6.86 (d, J

1

= 10.3Hz, 0.16H), 6.77 (s, 0.26H), 6.66 (d, J = 10.3Hz, 0.17H), 6.60 (d, J = 10.3Hz,
0.23), 6.59 (s, 0.25H), 6.46 (d, J = 10.3Hz, 0.26H), 6.41 (d, J = 10.3Hz, 0.26H),
6.28 (d, J = 10.3Hz, 0.25H), 6.19 (d, J = 10.3Hz, 0.26H), 6.02 (s, 0.16H), 5.92 (s,
0.20H), 5.21 (br, 1H), 4.98 (br, s, 1H) 4.77 (d, J = 19.0 Hz, 1H), 4.28 (d, J = 19.0Hz,
1H), 4.12 (m, 1.0H), 3.25 (s, 2H), 2.90 (m, 1H), 2.60 (m, 1H), 2.25 (m, 2H), 2.14
(m, 1H), 1.71 (m, 1H), 1.58 (m, 1H), 1.41 (d, J = 8.6Hz, 3H), 1.38 (d, J = 13.5Hz,
1H), 1.32 (m, 1H), 1.05 (m, 1H), 0.88 (s, 9H), 0.77 (d, J = 7.1Hz, 3H), 0.04 (s, 3H),
0.02 (s, 3H).
C NMR (125 MHz, DMSO-d6): δ (ppm) = 209.44, 174.80, 169.60, 157.62,
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156.88, 152.11, 151.27, 146.38, 146.05,144.35, 143.81, 142.95, 139.56, 138.87,
126.74, 120.70, 116.73, 116.67, 111.46, 111.32, 100.98 (d, J C-F = 173.4 Hz),
100.91 (d, JC-F = 172.3 Hz), 100.76 (d, JC-F = 173.4 Hz), 100.73 (d, JC-F = 172.6
22

Hz), 90.72, 90.66, 70.13 (d, JC-F = 37.4 Hz), 70.12 (d, JC-F = 37.3 Hz), 68.28,
47.74, 47.49 (d, JC-F = 21.5 Hz), 47.45 (d, JC-F = 21.5 Hz), 47.23, 44.15, 43.77,
42.72, 36.22, 36.17, 34.10 (d, JC-F = 19.5 Hz), 32.16, 31.19, 31.06, 30.20, 30.05,
27.58, 26.08, 24.55, 24.51, 24.19, 24.16, 24.10, 24.06, 18.45, 16.99, 15.52, 15.50,
-4.79, -4.93.
MS (ESI): m/z = 578.3 (M + H+), calculated: 577.3.
LC/MS: shows two peaks in the chromatography with the retention time at 3.91
min and 4.47 min were found with the same molecular weight at 578.347
(condition: A: 7.5 mM ammonium acetate, B: 95% MeOH and 5% Acetonitrile; A:B
= 30:70).

Synthesis of compound 5. Compound 4 (444 mg, 0.768 mmol) was dissolved in
anhydrous DMF (3 mL), followed by the addition of Fmoc-glutamic acid (135 mg,
0.366 mmol), HOBt (148 mg, 1.098 mmol) and DCC (226 mg, 1.098 mmol). The
resulting solution was stirred at room temperature for 4 hours. Ethyl acetate (100
mL) was then added to the solution and washed with brine (80 mL3). The
organic phase was separated and dried over MgSO4. After the solvent removal,
the residue was purified by flash chromatography (ethyl acetate:methanol =10:1)
to afford crude compound 5 (471 mg). The yield is 86.5%. TLC indicates the
presence of small amount of side products which were difficult to separate. The
crude product was used directly in the next reaction.

23

Synthesis of compound 6. Compound 5 (450 mg, 0.3 mmol) was dissolved in
DCM (4.5 mL) and cooled to 0°C. After addition of piperidine (1.5 mL), the
resulting solution was stirred at 0°C for 3 hours. Ethyl acetate (100 mL) was then
added and washed with brine (80 mL3). The organic phase was separated and
dried over MgSO4. After solvent removal, the residue was purified by flash
chromatography (ethyl acetate followed by ethyl acetate:methanol = 3:1) to
produce compound 6 (330 mg). The yield is 86.4%.

H NMR (500 MHz, DMSO-d6): δ (ppm) = 10.83 (m, 1.12H), 10.64 (m, 0.80H),

1

8.38 (m, 0.30H), 8.28 (m, 0.62H), 8.18 28 (m, 0.42H), 7.99 (m, 0.60H), 7.01 (m,
0.29H), 6.93 (m, 0.16H), 6.77 (s, 0.91H), 6.68 (s, 0.73H), 6.62 (m, 0.34H), 6.45
(m, 1.52H), 6.25 (m, 1.53H), 6.01 (s, 0.15H), 5.96 (0.31H), 5.17 (s, 1.0H), 5.15 (s,
1.0H), 4.95 (s, 2H), 4.77 (d, J = 19.1Hz, 2.0H), 4.28 (d, J = 19.1Hz, 2.0H), 4.19
(m, 0.53H), 3.95-4.15 (m, 4.91H), 3.70-3.90 (m, 1.68H), 3.26 (m, 1.54H), 2.90 (m,
2.15H), 2.55-2.75 (m, 3.93H), 2.15-2.35 (m, 5.23H), 2.05-2.15 (m, 5.04H), 1.87
(m, 1.10H), 1.72 (m, 3.07H), 1.59 (m, 2.23H), 1.41 (m, s, 6.87H), 1.31 (m, 3.38H),
1.05 (m, 1.99H), 0.87 (s, 18H), 0.85 (s, 6H), 0.77 (d, J = 6.9Hz), 0.03 (s, 6H), 0.02
(s, 6H)

MS (ESI): m/z = 1266.4 (M + H+), calculated: 1265.7.
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LC/MS: three peaks in the chromatography with the retention time at 5.07 min,
5.80 min and 6.54 were found with the same molecular weight of 1266.782
(condition: A: 7.5mM ammonium acetate, B: 95% MeOH and 5% Acetonitrile; A:B
= 18:82).

Synthesis of ZSJ-0228. DCC (107 mg, 0.52 mmol), hydroxybenzotriazole (HOBt,
70.2 mg, 0.52 mmol) and mPEG-COOH (100 mg, 0.052 mmol) were dissolved in
anhydrous DMF (3 mL) at room temperature and stirred for 1 hour. After addition
of compound 6 (428 mg, 0.338 mmol), the solution was stirred at room
temperature for 24 hours. LH-20 column was used to obtain the polymer fraction.
After removal of the solvent, the polymeric residue was dissolved in tetra-nbutylammonium fluoride (TBAF, 1 M, 2 mL) and stirred for 2 hours. The resulting
solution was again applied to LH-20 column to separate the polymeric fraction.
After dialysis against DI water overnight (MWCO = 2 kDa), the solution was
lyophilized to produce ZSJ-0228 (118.7 mg). The yield is 77.8%.

H NMR (500 MHz, DMSO-d6): δ (ppm) = 10.95 (s, 0.28H), 10.91 (s, 0.27H),

1

10.86 (s, 0.80H), 10.82 (s, 0.37H), 10.58 (m, 0.67H), 8.39 (m, 0.35H), 8.21 (s,
0.59H), 8.14 (m, 0.35H), 7.99 (m, 0.61H), 7.78 m, 0.30H), 7.71 (m, 0.69H), 7.54
(m, 0.1H), 7.02 (d, J = 10.3Hz, 0.53H), 6.90 (m, 0.26H), 6.78 (s, 0.69H), 6.606.71 (m, 1.25H), 6.42-6.47 (m, 1.14H), 6.27 (m, 0.41H), 6.21 (m, 0.73H), 6.00 (m,
0.26H), 5.96 (s, 0.53H), 5.14 (m, 1.98H), 4.93 (s, 1.85H), 4.66(m, 1.86H), 4.48

25

(dd, J = 19.2Hz, 5.8Hz, 1.80H), 4.40 (m, 0.67H), 4.34 (m, 0.40H), 4.00-4.25 (m,
6.66H), 3.92 (s, 2.55H), 3.86 (m, 0.52H), 3.83 (m, 0.36H), 3.51 (m, 183H), 3.25
(s, 3.24H), 2.93 (m, 1.92H), 2.63 (m, 1.43H), 2.36 (m, 0.66H), 2.20-2.35 (m,
5.71H), 2.05-2.15 (m, 4.46H), 1.97 (m, 1.45H), 1.84 (m, 1.16H), 1.71 (m, 2.15H),
1.60 (m, 2.48H), 1.42 (s, 7.95H), 1.31 (m, 2.55H), 1.23 (s, 1.07H), 1.05 (m, 2.12H),
0.84 (s, 6.00H), 0.77 (d, J = 7.1Hz, 5.74H).

MS (ESI): Two clusters of peaks were observed. One cluster is at around 1550,
which are diion peaks. For example: n=44, calculated: (Mn=44 + 2Na+)/2 =1546.4,
found 1546.7; n = 40, calculated: (Mn=40 + 2Na+)/2 = 1458.38, found 1458.3. The
other cluster is at around 1100, which are triion peaks, n = 46 calculated (M n=46 +
3Na+)/3 = 1068.0 found 1068.5.

MS (MALDI-TOF): One symmetric cluster of peaks (at about 3000) were observed,
which represent the molecular weights of ZSJ-0228 plus sodium ion.

For

example: Mn=41+Na+ = 2937.83, found 2938.28; Mn=43 + Na+ = 3025.84, found
3026.342; Mn=47 + Na+ = 3201.96, found 3202.425.

2.2.3 The Synthesis of Fluorescent-labeled ZSJ-0228
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The synthetic routes for IRDye 800CW-, Alexa Fluor 488- and Alexa Fluor
647-labeled ZSJ-0228 are similar to the unlabeled ZSJ-0228 (Scheme 2), except
the mPEG-COOH was replaced by Fmoc-NH-PEG-COOH.

After Fmoc

deprotection, the resulting NH2-containing polymeric prodrug (100 mg) was
dissolved in anhydrous DMF (1 mL) together with the NHS esters of IRDye
800CW (1 mg), Alexa Fluor 488 (1 mg) or Alexa Fluor 647 (1 mg). The solution
was stirred at room temperature for 15 hours. After LH-20 column purification,
fluorescent-labeled prodrugs were obtained.

Using a Spectramax M2

Spectrofluorometer, the IRDye 800CW, Alexa Fluor 488 and Alexa Fluor 647
contents were determined as 126.94±0.75 μmol/g, 145.88±3.1 μmol/g and
85.13±1.49 μmol/g, respectively.

2.2.4 Critical Micelle Concentration (CMC) Analysis

Pyrene-based fluorescence probe method was used to determine the critical
micelle concentration (CMC) of ZSJ-0228. For sample preparation, the stock
solution of pyrene (0.02 mg/mL, in acetone) was added to a 96-well plate. After
adding the aqueous solution of ZSJ-0228 at different concentrations to the wells,
the plate was left at room temperature for 2 hours to allow acetone evaporation.
The final pyrene concentration was maintained at 0.6 µM, which is slightly below
its water solubility at room temperature. After transferring to a quartz 96-well plate,
the fluorescence intensity was measured using a fluorescence microplate
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spectrofluorometer.

The excitation wavelength was set at 334 nm and the

emission wavelength at 373 nm (I1) and 384 nm (I3). The ratio of fluorescence
intensity I1/I3 was plotted against prodrug concentration to obtain the CMC
value.[102]

2.2.5 Dynamic Light Scattering (DLS) Analysis

The hydrodynamic diameter (Dh), -potential and polydispersity indices (PDI)
of micelles were determined with a Malvern Zetasizer Nano-ZS at 25°C at 90°in
triplicate. ZSJ-0228 were dissolved in ddH2O at designed concentration, filtered
through 20 µm syringe filter and vacuumed in the desiccator for 10 min to
eliminate air bubbles before measurement. Data were analyzed by the Zetasizer
software 7.12.

2.2.6 Nanoparticle Tracking Analysis (NTA)

The concentration and the size distribution of micelles were determined using
an NS300 NanoSight with a low-volume flow cell plate and a 405 nm laser. The
micelle solutions were pumped into the chamber using installed syringe pump.
The measurements were conducted at room temperature, replicated five times
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and further analyzed using NTA analytical software, version 3.2. Each video
sequence was captured over 60 seconds.

2.2.7 Transmission Electron Microscope (TEM) Analysis

To understand the micelles morphology, transmission electronic microscopy
(TEM) was used to visualize micelles at 80 kV. For sample preparation, one drop
of the ZSJ-0228 micelle solution (2 mg/mL) was deposited on the formvar/silicone
monoxide coated 200 mesh copper grids surface, and then dried overnight at
room temperature. The analysis was performed at 25°C.

2.2.8 Drug Loading Measurement by HPLC

To quantify the dexamethasone content in ZSJ-0228, the prodrug was
dissolved in HCl (0.5 mL, 0.1 N) and stirred overnight at room temperature. The
sample (50 µL) was withdrawn and neutralized by addition of NaOH (50 µL, 0.1
N), then diluted in acetonitrile (ACN, 0.9 mL). The sample (in triplet) was analyzed
using an Agilent 1100 HPLC system equipped with a reverse phase C 18 column
(Phenomenex, Bondclone H16-441537-C18, 300×3.9 mm, 10 µm). Mobile phase:
acetonitrile/water = 30/70; detection wavelength, 240 nm; flow rate, 1 mL/min;

29

Injection volume, 10 µL. The dexamethasone content in ZSJ-0228 was then
calculated based on the HPLC analysis result.

2.2.9 In Vitro Release Profile of Dexamethasone

To understand the impact of pH values on the release of dexamethasone from
ZSJ-0228, the prodrug (3 mg/mL) was dissolved in acetate buffers (pH = 4.5, 5.0,
6.5, and 7.4). Pluronic F127 (1 w/v % of buffer) was added as a surfactant to
create the “sink” condition.[103] The micelle solutions were incubated at 37 °C
with gentle agitation (60 r/min). At selected time points, the sampled releasing
solution (0.1 mL) was neutralized with NaOH (0.1 N) and analyzed with HPLC in
triplicate. The experiment was repeated three times in each pH buffer. The
accumulative release of dexamethasone from ZSJ-0228 micelles was calculated
according to the following equation, where 2 mL refers to the total volume of
release medium, 0.1 mL is the sampling volume, and Cn refers to the
concentration of dexamethasone at sampling time point n.

𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (𝑤𝑡%) =

2 𝑚𝐿 × 𝐶𝑛 + 0.1 𝑚𝐿 × ∑𝑛−1
𝑖=1 𝐶𝑖
× 100%
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑒𝑥𝑎𝑚𝑒𝑡ℎ𝑎𝑠𝑜𝑛𝑒 𝑖𝑛 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠

2.2.10 Statistical Analysis
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IBM SPSS 17.0 (IBM Corp., Armonk, NY, USA) or SAS 9.4 (SAS Institute, Cary,
NC, USA) were used for statistical analyses in this study. Continuous outcomes
were compared among ≥3 groups using the Analysis of Variance (ANOVA) or
Kruskal-Wallis tests.

Tukes post hoc t-test or Mann-Whitney U test with

Bonferroni method for multiple comparisons were used for the pairwise
comparisons.

2.3 Results

The main objective of this project is to develop a GC prodrug nanomedicine
with organ/tissue specificity to LN. We hypothesize that such an approach would
potentiate the GC’s efficacy and reduce systemic toxicities. As shown in Scheme
1, the prodrug (ZSJ-0228) was designed by conjugating two dexamethasone
molecules to a short methoxy polyethylene glycol’s (mPEG, 1.9 kDa) chain
terminus via a hydrazone/glycine/glutamate linker system.

The apparent

amphiphilicity of the prodrug allows its spontaneous self-assembly into micelles
in aqueous media, rendering the hydrophobic dexamethasone water-soluble.
According to the ELVIS mechanism, the systemically administered ZSJ-0228
would extravasate/filter at LN pathology, be sequestered by inflammatory cells
and activated kidney cells, and subsequently release dexamethasone within the
endosomal/lysosomal compartments (via the acid-cleavable hydrazone bond) to
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exert its localized anti-inflammatory and immune-modulating effects without
triggering systemic toxicities.

Scheme 1. The design of polyethylene glycol (PEG)-based amphiphilic
dexamethasone prodrug ZSJ-0228, which can self-assemble into micelles in
aqueous media. The oval shape highlights the dexamethasone structure.

2.3.1 The Synthesis of Amphiphilic Macromolecular Dexamethasone
Prodrug (ZSJ-0228)

ZSJ-0228 was successfully synthesized according to the route illustrated in
Scheme 2. The identity of the polymeric prodrug and the absence of free Dex
were confirmed with NMR, MS, and LC-MS/MS. The multi-step synthesis is
straightforward with high yield at each step. Tert-butyldimethylsilyl (TBS) was
introduced in the first step to protect the 21-hydroxyl group and to improve
solubility. The bulky presence of TBS sterically hinders access to the C-20
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carbonyl group, resulting in the formation of hydrazone bond predominantly at the
C-3, but not the C-20 carbonyl group. The presence of a local conjugation system
also favors the C-3 hydrazone formation. Because of the use of hydrazone as
the polymeric prodrug’s activation trigger, multiple configure isomers of compound
6 were formed, which could not be separated chromatographically.

Mass

spectrum (negative ion ESI) of the isomer mixture showed the molecular ion M+H +
at 1266.4 as a single peak (calculated molecular weight is 1265.7).

After

conjugation of compound 6 to mPEG-COOH, and the subsequent removal of the
TBS protection, the prodrug ZSJ-0228 was prepared.

The theoretical

dexamethasone content in ZSJ-0228 is calculated as 26.7 wt%. After complete
hydrolysis, HPLC analysis found 26.4 wt% of the prodrug we synthesized to be
dexamethasone, suggesting a ~ 99% purity.
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Scheme 2. The synthetic route for ZSJ-0228, a polyethylene glycol (PEG)-based
amphiphilic dexamethasone prodrug. Reagents and conditions: 1. TBSCl (1.1
equiv), Imidazole (2.0 equiv), DMF, 0°C, 3h, r.t. 2h, 98.5%; 2. NH2NH2 (3.0 equiv),
HOAc (0.2 equiv), MeOH, rt. 5h, 85.8% (brsm); 3. Fmoc-glycine (1.3 equiv), DCC
(1.5 equiv), DMAP (0.3 equiv), DMF, 0°C, 3h, 84.5% (crude); 4. Piperidine (3
equiv), dichloromethane; 0°C, 3h, 90.6%; 5. Fmoc-glutamic acid (0.48 equiv),
DCC (1.4 equiv), HOBt (1.4 equiv), DMF, rt., 4h, 86.5% (crude); 6. Piperidine (5
equiv), dichloromethane; 0°C, 3h, 86.4%; 7. M-PEG-COOH (0.15 equiv), DCC
(1.5 equiv), HOBt (1.5 equiv), DMF, rt., 24h; 8. TBAF (20 equiv), THF, rt., 2h, 77.8%
for

two

steps.

TBSCl:

tert-butylchlorodimethylsilane;

DCC:

N,N’-

dicyclohexylcarbodiimide; HOAc: acetic acid; DMAP: 4-dimethylaminopyridine;
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HOBt:

1-hydroxybenzotriazole;

DMF:

N,N-dimethylyformamide;

TBAF:

tetrabutylammonium fluoride; THF: tetrahedrofuran.

2.3.1 Characterization of ZSJ-0228 Micelles

As expected, the conjugation of hydrophobic dexamethasone dimer to the
hydrophilic mPEG led to amphiphilic ZSJ-0228 prodrug’s self-assembly into
micelles upon direct dissolution in aqueous media.

Using the pyrene-based

fluorescence probe method, the critical micelle concentration (CMC) value of ZSJ0228 was determined as 2.510-4 M.

Dynamic light scattering (DLS)

measurements (Figure 1A, Zetasizer Nano ZS90) revealed that the ZSJ-0228 can
form micelles with an average micelle diameter of 33 nm and a net charge close
to neutral. The DLS profile of the micelles was bimodal, suggesting the formation
of heterogeneous particle populations. As shown in the transmission electron
microscope (TEM) images, the micelles deposited on the substrate showed
heterogeneity, with the majority of micelles showing the average diameter of ~30
nm (Figure 1C) and the minority having a larger average diameter of ~100 nm
(Figure 1D).

Nanoparticle Tracking Analysis (NTA, Nanosight NS300) was

employed as an additional method to measure micelle size, distribution, and
relative concentration. The NTA result (Figure 1B) seems to be in agreement with
the DLS and TEM findings (as shown in Figure 1A, 1C, 1D), showing that the
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diameter of micelles was mostly < 41 nm (90 %) with a small population around
100 nm (10 %, Figure 2B, insert).

Figure 1. Characterization of ZSJ-0228 micelles. A. DLS profile of ZSJ-0228
micelles. The measurement was performed in triplicate. B. NTA measurement
of ZSJ-0228 micelles.

The measurements were repeated five times.

C.

Representative transmission electron microscope (TEM) image of ZSJ-0228
micelles. The average diameter of the micelles is estimated to be ~30 nm. D.
Representative TEM image of larger ZSJ-0228 micelle population with the
estimated average diameter of ~100 nm. Scale bar = 100 nm.
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As the dexamethasone activation trigger, the hydrazone bond in the ZSJ-0228
design should only be cleaved under acidic environment. This was confirmed in
an in vitro prodrug activation experiment (Figure 2) showing the near zero order
release of the conjugated dexamethasone with an almost constant rate at
~1.32 %/day and 0.96 %/day for four weeks in the pH 4.5 and pH 5.0 acetate
buffers, respectively. No dexamethasone release was detected in pH 6.5 and pH
7.4 buffers for the entire experiment duration.

Figure 2. The in vitro release of dexamethasone from ZSJ-0228 at different pH
values.

The experiment was done in acetate buffer (pH 4.5 and 5.0) and

phosphate buffer (pH 6.5 and 7.4) at 37°C.

Pluronic F127 (1 wt% of
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dexamethasone) was added to create the “sink” condition. Each experiment was
performed in triplicate. Results are expressed as mean ± SD.

2.4 Discussions

Based upon ELVIS mechanism, we previously have developed a
macromolecular prodrug of dexamethasone (P-Dex) using N-(2-hydroxypropyl)
methacrylamide (HPMA) copolymer as the carrier. The prodrug was found to
provide potent and long-lasting anti-inflammatory effect in multiple inflammatory
disease models, including the NZB/W F1 LN mice.[104-108] Mechanistically, this
pathophysiology-driven targeting of GC to nephritis is different from the active
kidney-targeting drug delivery, [109, 110] in which different targeting ligands (e.g.
peptides, sugar and folates, etc.) were employed to render the renal specificity.

While the therapeutic efficacy of P-Dex on the lupus model was strong and
sustained, it could only circumvent osteopenia, but other GC toxicities (e.g.
immunosuppression and adrenal gland atrophy, etc.) persist.[104]

Optical

imaging-based biodistribution studies and flow cytometry analyses of cells from
all major tissues/organs suggest that the persisted side effects may be attributed
to the prodrug’s internalization by circulating WBC and high-level deposition to
the mononuclear phagocyte system (MPS, including phagocytic cells of liver and
spleen).

This hypothesis was partially supported by the amelioration of
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splenomegaly in the P-Dex treated animals.[104] We posit that these off-target
distributions and gradual activation of P-Dex may have led to the sustained
presence of dexamethasone in the serum. While it may be at a low concentration
and not enough to cause skeletal deterioration, the serum dexamethasone level
can be sufficient to elicit systemic immunosuppression and adrenal gland
atrophy.[111]

With these understandings, we proceeded to develop the next generation
macromolecular GC prodrug, which is not only effective in resolving LN but also
able to avoid typical GC adverse effects found with P-Dex. The focus of our effort
was to further reduce dexamethasone levels in the serum by limiting the prodrug’s
sequestration by WBC and its deposition to the MPS.

Our previous findings suggest that the use of PEG as a prodrug carrier may
significantly delay cellular internalization when compared to the use of HPMA
copolymer carrier of the same size.[112] Therefore, we used PEG as the watersoluble drug carrier in the ZSJ-0228 design (Scheme 1). The selection of low
molecular weight mPEG 1900 was based upon the prior findings that polymeric
prodrugs with the lowest molecular weight demonstrate the highest kidney
exposure and relatively lower liver deposition.[113, 114] PEG with a molecular
weight of 0.4 or 1 kDa were not selected because they are mostly in wax or liquid
form, which can be difficult to handle and purify during the synthesis.

The
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amphiphilic structure of ZSJ-0228 allows its self-assembly into micelles in
aqueous media. Using DLS, TEM and NTA methods, we determined that the
ZSJ-0228 micelle’s average hydrodynamic diameter was around 30 nm, which
may lead to a long serum half-life should the micelle remain stable.[115] The
CMC value of the micelle, however, was determined to be relatively high (2.5104

M). This type of micelle will disintegrate upon i.v. administration and dilution,

significantly reducing its half-life in circulation. We anticipate that a shorter serum
half-life of ZSJ-0228 would limit its distribution to the liver and spleen when
compared to P-Dex,[113, 114] but still provide sufficient kidney exposure for
therapeutic effects.

A hydrazone bond was used as the ZSJ-0228 prodrug’s activation trigger.
The linker’s in vitro cleavage rate under acidic pH is relatively slow (Figure 2)
when compared to other hydrazone linker-based prodrug designs.[116] Such
slow activation kinetics may be explained by the presence of a large conjugation
system, which involves four double bonds including two C=C bonds within the A
ring of dexamethasone, one C=N bond, one C=O bond and the lone pair of SP2
electrons of the neighboring nitrogen.

The large delocalization of electrons

stabilizes the C-3 hydrazone and reduces the rate of C=N double bond cleavage
which is responsible for the release of dexamethasone.

When doxorubicin is

conjugated to HPMA copolymer via hydrazone bond,[116] such structural
stabilization does not exist. The slow in vitro hydrazone bond cleavage, however,
does not necessarily predict a slow in vivo prodrug activation. Also contributing
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to ZSJ-0228’s in vivo activation is the pH value within lysosomal compartments,
which can be significantly reduced under inflammatory conditions[117] and
accelerate the hydrazone bond cleavage. Other biochemical factors, such as the
elevated presence of reactive oxygen species (ROS), which is often associated
with inflammatory pathologies,[118] may also be considered as a trigger for
prodrug activation at inflammation.[119]
Due to the use of hydrazone as an activation trigger, ZSJ-0228 can have
multiple isomers. Since the activation product from these isomers is the same
(i.e. dexamethasone), and their ratio from different batches remains consistent,
the presence of these isomers in ZSJ-0228 are not a concern during the
preclinical Chemistry, Manufacturing, and Controls (CMC) development. Though
not used in our synthesis, we are aware of the development of single molecular
weight discrete PEG (dPEG), which has become commercially available.
Different from traditional macromolecular prodrug design, the use of dPEG in the
synthesis of ZSJ-0228 will produce a single molecular weight polymeric prodrug,
which will further reduce potential regulatory hurdles during the product
development.

2.5 Conclusions

A PEG-based dexamethasone prodrug was successfully synthesized. The
amphiphilic molecule self-assembles into micelles.

The chemical structure of
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PEG-Dex and self-assembled micelles were fully characterized. The results
demonstrated that PEG-Dex prodrug was successfully developed. Additionally,
critical micellar concentration (CMC), DLS, and TEM results confirmed the
micellar structure. Dexamethasone can be released in the acidic environment
(pH4.5~5), which provided the fundamental preconditions for the lysosome-based
controlled release in inflammatory kidney.
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CHAPTER III
DEXAMETHASONE PRODRUG MICELLES ATTENUATES
NEPHRITIS IN LUPUS-PRONE MICE WITHOUT APPARENT
GLUCOCORTICOID SIDE EFFECTS

3.1 Introduction

Systemic lupus erythematosus (SLE) or lupus is a chronic complex
autoimmune disease for which there is no cure. It is characterized by B and T cell
hyperactivation, overproduction of autoantibodies, and the deposition of immune
complexes in various tissues/organs. The symptoms of lupus among patients are
highly heterogeneous, which may include skin rash, arthritis, pericarditis,
neuropsychiatric disorders, and nephritis. The Lupus Foundation of America
estimates that 1.5 million Americans, and at least five million people worldwide,
have a form of lupus.[1] Lupus affects mostly women of childbearing age and has
a significantly higher prevalence among African Americans.[120] According to a
report by the U.S. Centers for Disease Control and Prevention in 2002, the death
rates attributed to lupus have increased by approximately 70% over a 20-year
period among African American women aged 45-64 years.[121]
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Nephritis is one of the most damaging complications of lupus. It is the leading
cause of morbidity and mortality among lupus patients. Around 35% adult lupus
patients in the US have clinical evidence of nephritis at the time of diagnosis. An
additional 15-25% patients will develop nephritis within ten years of their initial
diagnosis.[2] Lupus nephritis (LN) is initiated by abnormal immune complex
deposition on the basement membrane of renal glomeruli and the subsequent
activation of the immune effector cells (e.g. macrophages and neutrophils),
leading to damages of the renal tissues.[122] If not effectively managed, LN can
progress rapidly to impair renal function, and eventually results in kidney
failure.[123]

Among the limited treatment options,[124] glucocorticoid (GC) is one of the
most potent and widely used classes of medication for lupus. According to the
American College of Rheumatology (ACR)’s recent guidelines,[2, 61] a pulse GC
treatment followed by low/high-dose daily GC plus an immunosuppressive are
recommended as a standard treatment regimen for clinical management of
LN.[125]

Due to their potent anti-inflammatory efficacy and the lack of

alternatives,[126, 127] GC continue to be the mainstay for clinical management
of lupus symptoms.[2, 61] Some lupus pathologies, such as arthritis and skin
rash can be effectively managed with short-term GC. Serious lupus complications,
including progressive nephritis, however, necessitate long-term GC therapy,
which is often associated with severe adverse events involving the
musculoskeletal, endocrinal, hematopoietic, and cardiovascular systems.[128]
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The diverse biological effects of GCs are thought to be mediated via
transrepression, which elicits GC’s anti-inflammatory effects; and transactivation,
which is responsible for the GC-associated side effects.[129] Selective
glucocorticoid receptor modulators (SEGRMs) that can preferentially activate the
transrepression relative to the transactivation pathway have been developed.[130,
131] These compounds, however, do not exhibit strict pathway selectivity and
still produce GC-related side effects.[129, 132]

Recognizing the therapeutic potential of GC in the clinical management of LN,
their accompanying severe toxicities and the limited progress made in developing
SEGRMs, we proposed to address this challenge through the development of a
GC prodrug nanomedicine.

Conceptually, this approach is based upon an

inflammation targeting mechanism, which we discovered and termed as the
“ELVIS”.[133] It involves the Extravasation of the nanomedicine through Leaky
Vasculature at inflammation, and its subsequent Inflammatory cell-mediated
Sequestration, which would alter the pharmacokinetics/biodistribution (PK/BD)
profile of the parent drug, enabling its inflammatory tissues/organs specificity.
When tested in a spontaneous LN mouse model (female NZB/W F1 mice), the
GC prodrug (ZSJ-0228) nanomedicine we developed demonstrated superior
therapeutic efficacy than dose equivalent dexamethasone 21-phosphate
disodium (Dex) in ameliorating nephritis and improving kidney functions, with no
apparent GC toxicities.
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3.2 Materials & Methods

3.2.1 Materials & Instruments

The MTT cell proliferation assay was purchased from ATCC (Manassas, VA,
USA). Penicillin/streptomycin, Trypsin-EDTA, Dulbecco’s PBS, and RPMI 1640
were from Gibco (Grand Island, NY, USA). Fetal bovine serum was purchased
from BenchMark (Gemini Bio-Products, West Sacramento, CA). All solvents and
other reagents if not specified were purchased from Fisher Scientific or ACROS
and used without further purification.

In vivo near-infrared fluorescence (NIRF)-based optical imaging was
accomplished on an LI-COR PearlTM Impulse Small Animal Imaging System
(Lincoln, NE, USA).

Bone qualities were analyzed using a high-resolution

Skyscan 1172 micro-CT system (Bruker microCT, Kontich, Belgium).

Digital

images were acquired using a KeenView high-resolution camera and analyzed
using Soft Imaging Solutions AnalySIS ITEM digital software. The quantification
of fluorescence signal intensities of IRDye 800 CW, Alexa Fluor 488, Alexa Fluor
647 and pyrene were measured using Spectramax M2 spectrofluorometer
(Molecular Devices, Sunnyvale, CA, USA). The flow cytometry experiments were
performed on a BD LSRII Green flow cytometer (San Jose, CA, USA) and
analyzed using FlowJo software (Treestar, Inc., San Carlos, CA, USA). Confocal
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microscope images were acquired under an LSM 800 Zeiss Airyscan microscope
(Carl Zeiss, Oberkochen, Germany) and analyzed using ZEN Lite software.

3.2.2 Experimental Animals and Drug Treatment

Beginning at twenty weeks of age, NZB/W F1 female mice (Jackson
Laboratories, Bar Harbor, ME) were randomized into three groups (saline control,
Dex and ZSJ-0228). The urine protein level was monitored weekly using Albustix
Reagent Strips (Siemens Healthineers, Erlangen, Germany). Only mice with
established nephritis, as evidenced by sustained albuminuria (≥100 mg/dL) over
two weeks, were enrolled in the study.

ZSJ-0228 treatment (106 mg/kg,

containing 28 mg/kg of dexamethasone, n = 10) and saline (n = 12) were
administered as a monthly i.v. injection. A total of 2 injections of ZSJ-0228 were
given during the two months treatment period.

The Dex treatment

(dexamethasone 21-phosphate disodium, 1.32 mg/kg, containing 1.00 mg/kg of
dexamethasone, n = 11) was given as daily i.v. injection. All treatments continued
for eight weeks. The body weight and proteinuria level of the animals were
monitored weekly. Every four weeks, peripheral blood was sampled from the
saphenous vein for serum analyses. Mice that developed severe proteinuria (≥
2000 mg/dL) or showed signs of distress (e.g. reduced mobility, weight loss >
20 %, edema, unkempt appearance) were sacrificed immediately. At two months
post-treatment initiation, all surviving mice were euthanized by CO 2 asphyxiation,
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with major tissues and organs isolated, weighted and processed at necropsy. The
animal procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) of University of Nebraska Medical Center (UNMC).

3.2.3 Periodic Acid–Schiff (PAS) Staining and Pathological Scores

Paraffin sections from

mouse kidneys were deparaffinized, rehydrated,

washed with water, and stained with Periodic acid–Schiff (PAS) for evidence of
glomerulonephritis by light microscopy. Glomerulonephritis was assessed by a
pathologist

(KWF)

using

a

semi-quantitative

0-4

scale

as

described

previously.[134] Briefly, a score of 0 represents healthy condition; a score of 1
represents mild focal disease; a score of 2 represents moderate focal disease;
scores of 3 and 4 represent diffuse disease (namely severe glomerulonephritis).
The scores of 0, 1, 2, 3 and 4 indicate that 0, 1-19, 20-50, 51-75, >75% of the
glomeruli were affected. Fifty glomeruli per mouse were evaluated.

3.2.4 Immunohistochemistry Study

Immune complexes and macrophage infiltration were observed via
immunohistochemistry. Rabbit anti-mouse IgG (Abcam) and rabbit anti-mouse
F4/80 IgG (Abcam) were used as the primary antibodies. After deparaffinization
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and rehydration, a rabbit specific HRP/DAB (ABC) detection IHC kit (Abcam) was
applied. Briefly, the slides were first incubated in pH 6.0 citrate buffer (0.1 M),
washed, and then incubated in H2O2. The slides were blocked and incubated with
the primary antibodies.

Antibody binding was visualized using the DAB

chromogen. The staining intensity (represented as arbitrary gray units) of 50
glomeruli per mouse was quantified using Zeiss AxioVision software (version
4.6.3.0). Another set of slides stained for immune complexes and macrophages
were counterstained with hematoxylin; these slides were used for illustration
purposes only.

3.2.5 Immunofluorescence Study

For confocal microscopy, kidneys were dissected, fixed, dehydrated, and
frozen in 2-methyl-butane in a dry ice bath. Sections (20 µm) were cut on a
Bright's cryostat (Bright Instrument Co., Huntingdon, UK), thaw mounted onto
slides, and stored at -80°C until stained. The sections were stained with antimouse CD11b (Santa Cruz), CD 133 and CD146 (Abcam), and then incubated
with Alexa Fluor 488 labeled secondary antibody (Thermo Fisher Scientific,
Bremen). Cells were visualized via immunofluorescence under a Zeiss LSM
800confocal microscope. The images were processed using Carl Zeiss Zen 2.3
software.
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3.2.6 Analysis of Bone Quality

Femoral bone quality was analyzed using a Skyscan 1172 micro-CT system.
The scanning parameters were set as the following: voltage 48 kV, current 187
μA, exposure time 620 msec, resolution 6.07 μm, and aluminum filter 0.5 mm.
Three-dimensional reconstructions were achieved using NRecon and DataViewer
software (Bruker micro-CT). A consistent polygonal region of interest (ROI) of
trabecular bone at the distal femur, from 20 slices (0.25 mm) to 100 slices
proximal (1.25 mm) to the growth plate, was selected for bone quality analysis.
The mean bone mineral density (BMD), bone volume/tissue volume (BV/TV),
trabecular number and thickness were quantified using Bruker CTAn software.

3.2.7 Analysis of Serum Immunoglobulin and Autoantibody Levels

Serum levels of immunoglobulin were assessed via enzyme-linked
immunosorbent assay (ELISA). Total serum IgG levels were measured using a
commercial ELISA kit (Innovation Research). Serum anti-dsDNA IgG levels were
determined by ELISA (Alpha Diagnostic) as described previously.[106]

3.2.8 Near-infrared Optical Imaging
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After the proteinuria was established, NZB/W F1 mice and NZW mice were
given ZSJ-0228-IRDye (IRDye 800 CW dose at 148 nmol/kg, dexamethasone
equivalent dose of 28 mg/kg) via tail vein injection. At selected time points (1 and
4-day post-injection), the mice were euthanized and perfused with saline. All
major organs (i.e. heart, lung, liver, spleen, kidney and adrenal gland) were
isolated and imaged using an LI-COR PearlTM Impulse imager. The two imaging
time points (1 and 4-day post-injection) were selected to avoid the early dynamic
distribution phase when the prodrug concentrations in different organs and tissues
change dramatically in a short period of time. All images were collected under
the channel of 800 nm with the same resolution (170 μm) settings.

3.2.9 Flow Cytometry Analysis
After the proteinuria was established, NZB/W F1 mice (n = 3 for each time
point) and NZW mice (n = 5 for each time point) were given ZSJ-0228-AF647
(Alexa Fluor 647 dose at 300 nmol/kg, dexamethasone equivalent dose of 28
mg/kg) via tail vein injection. The animals were euthanized and perfused at 1 and
4-day post-administration. Blood, bone marrow, heart, lung, kidney, liver and
spleen were harvested and processed to obtain single-cell suspensions. These
cells were marked by the following antibodies: BV711-labeled anti-mouse CD11b,
BV786-labeled anti-mouse CD3e, BUV395-labeled anti-mouse NK1.1, PerCPCy5.5 labeled-CD146, PE-Cy7-labeled CD19, BV510-labeled anti-mouse CD11c,
APC-eFluor 780-labeled anti-mouse Ly-6G (BD Biosciences), APC-labeled anti-
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mouse F4/80 and PE-labeled anti-mouse CD326 (eBioscience Inc.). The cells
were analyzed using a BD LSR II Green flow cytometer with FlowJo software.

3.2.10 Cell Culture Study

The cell viability was quantified using the 3-[4, 5-dimethylthiazol-2-yl]-2, 5
diphenyltetrazolium bromide (MTT) cell proliferation assay from ATCC (Manassas,
VA, USA). Briefly, human proximal tubule epithelial (HK-2) cells28 were seeded
in 96-well plates (1104 cells/well) overnight and treated with different
concentrations of ZSJ-0228 (0.01 - 2000 μM dexamethasone equivalent), Dex
(0.01 μM – 2000 μM dexamethasone equivalent) and mPEG (0.005 – 1000 μM
ZSJ-0228 equivalent). PBS was used as a control. The cells were incubated for
24, 48 and 72 hours. At each time point, 10 μL MTT was added to each well and
incubates at 37 ºC for 4 hours. MTT detergent reagent (100 μL/well) was added
to dissolve the insoluble formazan, then incubated for 2 hours in dark at room
temperature. A microplate reader (Fisherbrand™ accuSkan™ FC Filter-Based
Microplate Photometer) was then used to measure the UV absorbance at 570nm
and 660nm (reference wavelength). The cell viability results are presented as the
percentage of PBS control (100 %).

3.2.11 In Vitro Internalization Kinetics Study
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To investigate the internalization of Alexa Fluor 488-labeled ZSJ-0228 (ZSJ0228-AF488), HK-2 cells were seeded on the 24-well plastic plate and incubated
overnight with lipopolysaccharide (LPS, 10 μg/mL) to mimic the lupus nephritis
condition. ZSJ-0228-AF488 (final concentration of 200 μg/mL) was added to LPSstimulated HK-2 cells.

The HK-2 cells without LPS treatment were used as

control. At 1, 4, 24, 48 and 72-hours’ time intervals, the cells were rinsed, fixed
and analyzed by flow cytometry.

3.2.12 Immunocytochemistry Study

For the subcellular localization studies, HK-2 cells were cultured overnight
with LPS and then incubated with ZSJ-0228-AF488 (200 μg/mL) for 24 hours on
the cover clips in the 24-well plates.

Cells were rinsed and incubated with

LysoTracker DND-99 (Invitrogen, 75 nM) for 3 hours. Then the cells were rinsed,
stained with DAPI, fixed, mounted, and observed under confocal microscope.

3.2.13 Statistical Analysis

IBM SPSS 17.0 (IBM Corp., Armonk, NY, USA) or SAS 9.4 (SAS Institute,
Cary, NC, USA) were used for statistical analyses in this study. Continuous
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outcomes were compared among ≥3 groups using the Analysis of Variance
(ANOVA) or Kruskal-Wallis tests. Tukey’s post hoc t-test or Mann-Whitney U
test with Bonferroni method for multiple comparisons were used for the pairwise
comparisons. The outcome of surviving rate was compared among three groups
using Log-rank Mantel-Cox test. Multiple comparisons was corrected with
Bonferroni’s method. The binary outcome of having proteinuria reading values of
2 and above at the 8-week time point was compared among three groups using
the Fisher’s exact test. Bonferroni’s pairwise comparison was used to control for
multiple testing. The generalized estimating equation (GEE) method was used to
model the repeated measurements of a continuous outcome to account for the
correlation within the subject. The GEE method is robust to the misspecification
of the distribution of the outcome. Tukey’s pairwise comparison between groups
was performed to control for multiple testing in the GEE model.

3.3 Results

3.3.1 ZSJ-0228 Effectively Ameliorated Proteinuria and Improved the
Survival of NZB/W F1 Mice with Established Nephritis

The therapeutic effects of ZSJ-0228 were evaluated in NZB/W F1 female mice
(~ 28 weeks old) with fully developed nephritis (proteinuria ≥ 100 mg/dL for two
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weeks). The mice were given two monthly intravenous injections of ZSJ-0228 (28
mg/kg, dexamethasone equivalent).

Dose equivalent daily Dex (1 mg/kg,

dexamethasone equivalent, i.v.) 18 and monthly saline administration (i.v.) were
used as controls. At the end of two months, all animals were euthanized. As
shown in Figure 3A, the mice in saline group maintained a 100% incident rate of
proteinuria. Eight out of twelve mice (75 %) demonstrated increased proteinuria
level over the course of the experiment, with albustix reading increased from 2 to
4. For the Dex treatment group, the level of proteinuria increased in 36% of the
mice (albustix reading increased from 2 to 4) and was normalized in 18% of the
mice (albustix reading decreased from 2 to 1), suggesting that the Dex treatment
can partially impede LN progression. In the ZSJ-0228 treatment group, only one
mouse showed an increased level of proteinuria, with albustix reading increased
from 2 to 4. Three mice maintained the same level of proteinuria (albustix reading
at 2). The levels of urine proteins for the rest of the mice (60%) was normalized,
with albustix reading decreased to 0 or 1. This result is significantly better than
the saline control (P < 0.01), suggesting that the prodrug treatment is very
effective in the amelioration of LN.

ZSJ-0228 treated NZB/W F1 mice also showed a significantly better survival
rate than the saline control mice (P < 0.05). Before the end of the treatment (mice
at 36 weeks of age), a total of 42% of mice in the saline group died due to severe
nephritis (Figure 3B). This is in general agreement with the literature reports of
the median survival of saline-treated NZB/W F1 female mice (~ 35 weeks).[104,
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134-136] In comparison, two out of eleven mice treated with Dex died, and all
ZSJ-0228 treated mice survived. The apparent trend of ZSJ-0228 group’s better
survival rate than the Dex group did not reach statistical significance (P = 0.17).
All deceased animals exhibited the highest level of proteinuria (albustix reading
at 4) before death.

Figure 3. Monthly ZSJ-0228 treatment demonstrates superior therapeutic
efficacy when compared to dose equivalent daily Dex treatment. A. Monthly ZSJ0228 treatment normalized albuminuria among 60% of NZB/W F1 mice (with
established nephritis), while dose equivalent daily Dex treatment only normalized
18 % at the end of 2-months treatment. PT = pretreatment. The percentages
shown accounted for those animals with proteinuria reading value of 2 and above
at the 8-week time point. Each data point represents an individual mouse. P =
0.003, Fisher's exact test. B. Kaplan-Meier survival curves for ZSJ-0228, Dex
and saline treatment groups are shown. Only ZSJ-0228 treatment results in 100%
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survival after two months treatment, which is significantly better than Saline
control (*, P < 0.05). No significant difference between ZSJ-0228 and Dex groups
was found (P = 0.17). Log-rank Mantel-Cox test with Bonferroni correction.

To further validate the superior therapeutic efficacy of ZSJ-0228, kidneys
isolated at necropsy were sectioned, stained with Periodic acid–Schiff (PAS) and
evaluated by a pathologist (KWF, who was blinded to the grouping arrangement).
The tissue sections were graded using a histopathologic scoring system with a 4point scale.[134] Compared to the ZSJ-0228-treated mice, more than 40% of
saline and Dex-treated mice had a higher percentage of damaged glomeruli
(scoring 3 and 4 points).

Evidence of acute glomerular injury included

endocapillary hypercellularity as well as the presence of wire-loop lesions,/hyaline
thrombi (indicating immune complex deposition), cellular crescents, etc. (Figure
4). In contrast, only ~11% of the mice in ZSJ-0228 treated group was graded with
severe glomerulonephritis (with the rest in the mild and moderate categories),
which was much lower than that of the saline (~43%) and Dex (~44%) groups. In
addition, when individual glomeruli were evaluated histologically, abnormities
were observed in 26% glomeruli from ZSJ-0228 treated mice, which is close to
the frequency (21.6%) found in the NZW mice (healthy control, which do develop
anti-dsDNA antibodies, high serum levels of retroviral gp70 antigen, and nephritis
later in life [137]). Compared to this observation, 40% and 52% glomeruli in Dex
and saline groups were found to be abnormal, respectively.

Though these
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differences are not statistically significant (P = 0.19), the apparent trend further
supports the superior efficacy of ZSJ-0228 in treating LN (Figure 4F).
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Figure 4. Histological evaluation of kidneys from different treatment groups. The
tissues were formalin-fixed, sectioned (3 μm) and stained with Periodic acid–
Schiff (PAS) for visual examination and grading by a pathologist (KWF), who was
blinded to the group design. A. PAS-stained kidney section from the saline group
showing wire-loop lesions (arrow). B. PAS-stained kidney section from the Dextreated group showing a cellular crescent (arrow). C. PAS-stained kidney section
from ZSJ-0228 treated group, showing less severe glomerular injury with a
healthier appearance similar to the NZW control. D. PAS-stained kidney section
from NZW control group. All scale bar = 50 μm. E. The fractions of mice in each
group with mild, moderate and severe renal disease. Results are expressed as
percentage of mice with indicated disease severity. F. The average percentage
of abnormal glomeruli found in each group. Results are expressed as mean ±SD.
No statistically significant difference was found among the groups. P = 0.19, oneway analysis of variance or ANOVA with Bonferroni Tukey’s correction.

3.3.2 ZSJ-0228 Treatment Showed No Apparent GC Toxicities

The viability of HK-2 cells (an immortalized renal proximal tubule epithelial cell
line from the normal adult human kidney) was evaluated after 72 hours incubation
with ZSJ-0228, Dex and mPEG. As can be seen in Figure 5, ZSJ-0228 and Dex
showed minimal cytotoxicity to HK-2 cells within the tested range of
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dexamethasone equivalent concentrations (0.01 – 2,000 μM). mPEG was also
found to be non-toxic.

Figure 5. Impact of mPEG, ZSJ-0228, and Dex on HK-2 cell viability after 72 h of
incubation, as assessed by the MTT assay. For ZSJ-0228 and Dex, they were
tested at dexamethasone equivalent concentrations (0.01−2000 μM). mPEG was
tested at ZSJ-0228 equivalent concentrations (0.005−1000 μM). Each ZSJ-0228
has one mPEG and two dexamethasone molecules.

During the two months treatment study, no significant difference in body
weight was observed among ZSJ-0228, Dex and saline groups (Figure 6). On
average, all tested groups maintained within 90% of original body weight at the
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end of the two months treatments. Different from saline and ZSJ-0228 groups,
an early trend of body weight decrease was observed in the Dex group,
suggesting potential adverse effects of the treatment (Figure 6). It is important to
note that several mice from the saline and Dex groups have died earlier (Figure
3B) due to severe nephritis and significant loss of body weight (> 20%). Their
body weight values at the time of death were recorded. Should they be living at
the end of the two months treatment, significant difference among the three tested
groups may be observed.

Figure 6. Body weight (% of week 0) of NZB/W F1 mice during the two-month
treatments with ZSJ-0228 and Dex (dexamethasone dose equivalent). Saline was
used as a control. ZSJ-0228 treatment did not affect the mice body weight. An
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early trend of decreased body weight was observed in the Dex group, suggesting
a potential adverse effect of the treatment.

One of the major adverse effects associated with GC use is osteopenia. To
understand the impact of ZSJ-0228 treatment on the skeleton, we evaluated the
femoral bone quality using a high-resolution micro-CT (Skyscan 1172). The bone
mineral density (BMD) and trabecular thickness in the femoral trabecular bone of
ZSJ-0228 treated mice were significantly higher than those from the saline and
Dex-treated groups (Figure 7A and 7C; P < 0.05).

A trend toward higher

trabecular bone volume/tissue volume (BV/TV) value was also observed (Figure
7B, P = 0.69).
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Figure 7. ZSJ-0228 treatment does not affect the bone quality of lupus prone
mice. (A) ZSJ-0228 treatment is significantly better at preserving bone mineral
density than Dex treatment and the saline controls. (B) ZSJ-0228-treated mice
trended toward a higher bone volume/tissue volume than Dex treatment and
saline controls (P = 0.69). (C) ZSJ-0228-treated mice have a significantly higher
trabecular thickness value than Dex treatment and saline controls. For bone
quality (A, B, and C), samples were available for analysis only from the subset of
mice surviving at the final time point (8-week): 10 mice for the ZSJ-0228 group, 9
mice for the Dex group, 7 mice for the saline group. Results are expressed as
mean ± SD. Statistical analysis of data in panels A and C was performed using
the Kruskal−Wallis test with Bonferroni’s pairwise comparison. For panels B, the
statistical analysis was performed using one-way ANOVA with Tukey’s pairwise
comparison. *, P < 0.05, **, P < 0.01.

Chronic exposure to GC therapy is known to be associated with systemic
immunosuppression. To understand if ZSJ-0228 as a GC prodrug would be
similarly immunosuppressive, we evaluated the total serum IgG level and the
peripheral white blood cell (WBC) counts at designated time points. As shown in
Figure 8A, ZSJ-0228 treated mice exhibited similar WBC counts as the saline
group, but the value is significantly higher than that of the Dex-treated mice (P <
0.05). As shown in Figure 8B, total serum IgG levels were not altered in the ZSJ0228 treated mice during the treatment. In contrast, the animals treated with daily
Dex had a significant drop of serum IgG value after only one month of treatment
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(P < 0.001) and continued to the end of the experiment (P < 0.0001). These data
collectively suggest the immune system is not being further suppressed in animals
treated with ZSJ-0228.

Figure 8. ZSJ-0228 does not elicit apparent immunosuppression in the circulating
blood system. (A) The average white blood cell (WBC) count of the ZSJ-0228treated mice was similar to that of the saline group, but was significantly higher
than the Dex group. (B) Total serum IgG levels for mice in ZSJ-0228 (n = 10), Dex
(n = 11), and saline (n = 12) groups were determined by ELISA at pretreatment,
4-week, and 8-week time points. The ZSJ-0228 treatment did not significantly
reduce total serum IgG levels, whereas Dex treatment did, suggesting potential
immune suppression. Fore WBC counts (A), samples were available for analysis
only from the subset of mice surviving at the final time point (8-week): 10 mice for
the ZSJ-0228 group, 9 mice for the Dex group, 7 mice for the saline group. For
total serum IgG levels (B), the ZSJ-0228 group has 10 mice at 4-week and 8week time points; the Dex group has 11 and 9 mice at the 4-week and 8-week
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time points, respectively; and the saline group has 11 and 7 mice at the 4-week
and 8-week time points, respectively. Results are expressed as mean ± SD. For
panels A, the statistical analysis was performed using one-way ANOVA with
Tukey’s pairwise comparison. For panel B, the statistical analysis was performed
using the generalized estimating equation (GEE) method with Tukey’s pairwise
comparison. **, P < 0.01, ****, P < 0.0001.

GC exposure, even in the short-term, is known to suppress hypothalamicpituitary-adrenal (HPA) axis, leading to clinical atrophy of the adrenal gland.[138]
To understand if ZSJ-0228 treatment would cause adrenal gland atrophy in
NZB/W F1 mice, the adrenal glands from all treatment groups were isolated and
weighed at necropsy. The mean value of adrenal gland mass in the Dex group
was significantly lower than that from the ZSJ-0228 group (Figure 9; P < 0.05).
No significant difference in adrenal gland mass was found between the ZSJ-0228
and saline groups (Figure 9; P = 0.22). These data suggest the treatment with
ZSJ-0228 does not lead to adrenal gland atrophy.
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Figure 9. Different from Dex treatment, ZSJ-0228 treatment did not induce
adrenal gland atrophy. Samples were available for analysis only from the subset
of mice surviving at the final time point (8-week): 10 mice for the ZSJ- 0228 group,
9 mice for the Dex group, 7 mice for the saline group. Results are expressed as
mean ± SD. Statistical analysis of data in this panels wa performed using the
Kruskal−Wallis test with Bonferroni’s pairwise comparison. **, P < 0.01.

3.3.3 ZSJ-0228 Treatment Ameliorates Renal Immune Complexes but does
not Alter Serum Anti-dsDNA Level

GCs have been shown to exert some of its therapeutic effects on lupus
partially through the down-regulation of anti-dsDNA antibody levels.[139]
Therefore, it was important to evaluate whether ZSJ-0228 attained its therapeutic
effect through this mechanism. As shown in Figure 10, ZSJ-0228 treatment
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showed no impact on serum anti-dsDNA IgG during the treatment. But, it was
found to significantly reduce renal immune complex deposition when compared
to the saline control. Daily Dex treatment, on the other hand, was found to
significantly reduce serum anti-dsDNA IgG level at 4- and 8-weeks post-treatment
initiation (P<0.05); but had no impact on renal immune complex deposition.
These results suggest that the immunosuppressive effect of ZSJ-0228 is not
systemic but restricted to the inflamed kidneys.
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Figure 10. The effect of different treatments on the renal immune complexes
deposition and serum anti-dsDNA IgG levels. ZSJ-0228 treatment was found to
significantly reduce renal immune complexes deposition.

While Dex daily

treatment significantly reduced the serum anti-dsDNA IgG level, it had no impact
on renal immune complexes deposition. A. Representative kidney sections from
each treatment group, immunohistochemically stained for renal deposition of anti69

mouse IgG. Scale bar = 50 µm. B. Quantification of kidney immune complex
staining. Results are expressed as mean ± SD. *, P < 0.05, one-way ANOVA
test with Tukey’s correction; C. Serum anti-dsDNA IgG levels at the pretreatment,
4-week, and 8-week time points, as determined by enzyme-linked immunosorbent
assay. Results are expressed as mean ± SD. Statistical analysis of the data in
panel C was done using GEE method with Tukey’s pairwise comparison.

3.3.4 ZSJ-0228 Reduced Renal Macrophages Infiltration

To further understand ZSJ-0228’s working mechanism, we examined the
infiltration of macrophages into the kidney, an indicator of chronic renal
inflammation. The macrophage marker F4/80 was used in kidney tissue sections
from all the treatment groups (Figure 11A). Quantification of F4/80 staining
suggested that Dex treatment did not significantly reduce macrophage infiltration
when compared to the saline control.

In contrast, ZSJ-0228 treatment

significantly lowered the renal macrophage level when compared with Dex
treatment and saline control (Figure 11B). These results suggested that the ZSJ0228 treatment may partially exert its therapeutic effects through ameliorating
macrophage infiltration to the kidneys.
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Figure 11. Impact of different treatments on renal macrophage infiltration. A.
Representative

kidney

sections

from

each

treatment

group,

immunohistochemically stained for renal deposition of anti-mouse F4/80. Scale
bars = 50 µm. B. Quantification of immune complex staining.

Results are

expressed as mean ± SD, *, P < 0.05, Kruskal-Wallis test with Mann-Whitney
correction.

3.3.5 ZSJ-0228 Targeted the Nephritic Kidneys in NZB/W F1 Mice

To understand the therapeutic efficacy and reduced GC-associated toxicities
of ZSJ-0228, the in vivo biodistribution of ZSJ-0228 was qualitatively analyzed
using near-infrared optical imaging. Both NZB/W F1 and NZW mice (healthy
control) received i.v. injections of IRDye 800 CW-labeled ZSJ-0228 (ZSJ-0228IRDye). As shown in Figure 12A, in NZB/W F1 mice, ZSJ-0228-IRDye primarily
accumulated in the kidneys and could be detected for at least four days. ZSJ0228-IRDye was also found to accumulate in NZW mice’s kidneys, but the
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intensity of the signal was at a much lower level, especially at 4-day postadministration. These observations seem to suggest that the severe nephritis of
NZB/W F1 mice may have contributed to the targeting and retention of ZSJ-0228
in the kidneys.

To better appreciate the kidney retention mechanism of ZSJ-0228 on the
cellular level, Alexa Fluor 647-labeled ZSJ-0228 (ZSJ-0228-AF647) was i.v.
administered to NZB/W F1 and NZW mice. All major organs, including kidneys,
were processed for flow cytometry analysis at 1 and 4-day post-injection. As
shown in Figure 12B, ~56% of kidney cells from NZB/W F1 mice were positive for
ZSJ-0228-AF647, while only ~38% of kidney cells from NZW mice were ZSJ0228-AF647 positive. The presence of ZSJ-0228-AF647 positive cells in other
organs were all less than 10%. For NZW mice, the percentage of ZSJ-0228AF647 positive cells at 4-day post-injection decreased significantly (to ~23%, P <
0.0001) when compared to the value at 1-day post-injection. No significant ZSJ0228-AF647 positive cell reduction was observed in kidneys of NZB/W F1 mice
from 1 to 4-day post-injection. These flow cytometry data confirm ZSJ-0228AF647’s targeting to the inflamed kidneys of NZB/W F1 mice found in the optical
imaging study and attributes the prodrug’s retention in the kidney to cell-mediated
sequestration.
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Figure 12. The targeting and retention of ZSJ-0228 in the kidneys of NZB/W F1
mice. A. Representative optical images of organs isolated from NZB/W F1 mice
and NZW mice (healthy control). Images were obtained at 1 and 4-day post i.v.
injections of IRDye 800 CW-labeled ZSJ-0228 (ZSJ-0228-IRDye). Pseudo colorcoded signal intensity reflects the level of ZSJ-0228-IRDye within the organ
examined. All the images were acquired with the same condition and share the
same color bar. Ht, heart; Lv, liver; Kd, kidney; Sp, spleen; Lu, lung; BL, blood;
BM, bone marrow. B. Flow cytometry analysis of cells isolated from organs of
NZB/W F1 and NZW mice at 1 and 4-day post i.v. injections of Alexa Fluor 647labeled ZSJ-0228 (ZSJ-0228-AF647). Results are expressed as mean ±SD. ****,
P < 0.0001, one-way ANOVA with Bonferroni Tukey’s correction.

3.3.6 Profiling of Kidney Cells that Internalized ZSJ-0228
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Additional flow cytometry analysis was performed to further profile the ZSJ0228-AF647 positive cells in the kidneys after systemic administration of the
prodrug. In the nephrotic kidney, ~70% CD11b+ (myeloid) cells internalized ZSJ0228-AF647 at 1-day post-injection; these cells include CD11c+ (dendritic cell),
NK1.1+ (natural killer cell), Ly6G+ (neutrophil) and F4/80+ (macrophage)
subphenotypes [140] (Figure 13A). At 4-day post-injection, ~50% of these cells
still remain positive for the prodrug. In comparison, ~30% of the myeloid cells in
NZW mice group internalized the prodrug at 1-day post-injection, and only onethird of the cells remained positive for the prodrug at 4-day post injection.
Moreover, ~60% of the CD326+ (proximal tubular epithelium) and CD146+
(endothelium) cells in nephrotic kidneys retained ZSJ-0228-AF647 at 4-day postinjection, which is 50% higher than the control kidneys. These results suggest
that both inflammatory cells and resident renal cells (including CD326+ and
CD146+ cells) in the nephrotic kidneys have sequestered ZSJ-0228 and retained
it as compared to the control.

To account for ZSJ-0228-AF647’s cellular

distribution pattern, ~20-40% of the prodrug was found in the CD11b+ cells of the
nephrotic kidney, with less than 10% in the control kidneys (Figure 13B). Around
30-40% of ZSJ-0228-AF647 was internalized by the CD326+ cells of both NZB/W
F1 and NZW mice, suggesting that the prodrugs primarily distribute to the renal
myeloid cells and proximal tubular epithelium. The rest of the ZSJ-0228-AF647
positive cells remain unidentified due to the lack of specific marker.
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Figure 13. Profiling the cellular internalization and retention of ZSJ-0228 by
kidney cells. Flow cytometry was used to analyze cells isolated from kidneys of
NZB/W F1 and NZW mice at 1 and 4-day post-injection of ZSJ-0228-AF647. A.
The percentage of renal cells internalized ZSJ-0228-AF647. B. The percentage
of ZSJ-0228-AF647 internalized by different cells in the kidney. Results are
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expressed as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001,
one-way ANOVA with Bonferroni Tukey’s correction.

To validate renal cells’ sequestration of ZSJ-0228-AF647 (red) observed by
flow

cytometry,

nephrotic

kidneys

were

harvested,

sectioned,

and

immunohistochemically stained at 1-day post i.v. administration of the prodrug for
confocal microscope analysis. As can be seen in Figure 13, fluorescent signal
co-localization of CD133 (injured/activated proximal tubular epithelial cell[141]),
CD146 (endothelium), or CD11b (myeloid cells) with ZSJ-0228-AF647 was
observed at both low and high magnification images.

This confirms the

sequestration of ZSJ-0228-AF647 by these cells in the nephrotic kidney, which
further support the findings in Figure 13.
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Figure 14. Immunohistochemical analysis of kidney cells’ sequestration of ZSJ0228-AF647. NZB/W F1 mice were i.v. administered ZSJ-0228-AF647 (red) and
euthanized at 1-day post-injection. Kidneys were sectioned and stained with antimouse CD133, CD146, and CD11b (green). Nuclei were stained with DAPI (blue).
Merged images were shown at the right panels. The higher magnification (63)
images were shown within the lower magnification (10) images at the lower left
corner. Scale bar = 100 μm.

3.3.7 Internalization Kinetics and Subcellular Location of ZSJ-0228
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As an immortalized renal proximal tubule epithelial cell (RPTEC) line from
normal adult human kidney, HK-2 cells can reproduce experimental results
obtained with freshly isolated RPTECs on the basis of its histochemical,
immunocytochemical, and functional characteristics.[142] As RPTEC represents
one of the main cellular populations identified to sequester ZSJ-0228, HK-2 cell
culture was used to recapitulate the internalization kinetics of prodrug and its
subcellular location. Alexa Fluor 488-labeled ZSJ-0228 (ZSJ-0228-AF488) was
used in this particular experiment. As shown in Figure 15A, HK-2 cells rapidly
internalized ZSJ-0228-AF488 and the fluorescent signal intensity increased over
time.

Inflammatory conditions are known to be associated with accelerated

endocytosis.[143, 144] The introduction of lipopolysaccharide (LPS), however,
did not accelerate the internalization process as anticipated, suggesting it may
not be sufficient to recapitulate the in vivo inflammatory environment.

To define the subcellular location of ZSJ-0228 in HK-2 cells, the cells were
incubated with ZSJ-0228-AF488 and LysoTracker (lysosome marker, DND-99,
red) and then examined under the confocal microscope.

The partial co-

localization of internalized ZSJ-0228-AF488 (green) with DND-99 (red) indicates
that ZSJ-0228 was endocytosed and processed in the acidic lysosomal
compartment, which is ideal for the hydrazone-based acid cleavable ZSJ-0228
prodrug design (Figure 15B).
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Figure 15. In vitro internalization kinetics and subcellular location of Alexa Fluor
488 labeled ZSJ-0228 in human proximal tubule epithelial (HK-2) cells. A. The
cellular internalization kinetics of ZSJ-0228-Alexa 488 by HK-2 cells with or
without lipopolysaccharide (LPS, 10 μg/mL) activation over a 72-hour time course.
Results are expressed as mean ± SD.

B. Representative confocal images

exhibiting internalization and subcellular trafficking of ZSJ-0228-AF488 in LPSactivated (10 μg/mL) HK-2 cells. LysoTracker DND-99 signal (red), ZSJ-0228AF488 signal (green), DAPI signal (blue). Scale bar = 20 μm.

3.4 Discussions

Previously, daily dexamethasone treatment (1 mg/kg) was found to attenuate
the nephritis and improve survival of NZB/W F1 mice.[145] In the present study,
it was used as a benchmark to compare with ZSJ-0228 prodrug treatment. Dose
equivalent monthly Dex treatment (28 mg/kg dexamethasone equivalent) was not
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used as a control due to severe adverse events observed immediate after
administration. As anticipated, when tested in NZB/W F1 mice with established
nephritis, ZSJ-0228 monthly treatment effectively attenuated albuminuria and
maintained 100% animal survival for the entire experimental duration. Dose
equivalent daily Dex treatment (1 mg/kg), on the other hand, only presented with
moderate efficacy and 80% survival (Figure 3). These observations were further
supported by the glomerular histologic findings in which ZSJ-0228 treatment was
found to more effectively prevent glomerular injury with disease severity rated
mostly mild to moderate (Figure 4).

ZSJ-0228 seems to also possess an improved safety profile. As shown in
Figure 5 A, ZSJ-0228 showed minimal cytotoxicity in HK-2 cells culture. During
the two-month treatment study, the prodrug treatment did not significantly alter
the mice’s body weight (Figure 6). Compared to dose equivalent daily Dex
treatment, the monthly ZSJ-0228 treatment did not induce osteopenia (Figure 7AC); neither did it cause immunosuppression as evidenced by WBC and total
serum IgG levels comparable to the saline group (Figure 8A&B). Furthermore,
mice treated monthly with ZSJ-0228 were found to have significantly higher
adrenal gland mass than the dose equivalent daily Dex-treated mice, suggesting
the absence of adrenal gland atrophy (Figure 9). It is very important to recognize
that the WBC reduction induced by GC treatment is being interpreted as
immunosuppression in NZB/W F1 mice.[146]

It is well-recognized that the

opposite effect (i.e. leukocytosis) is commonly observed in human patients when
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GC is being used[147] Therefore, ZSJ-0228’s impact on WBC in the NZB/W F1
mice should not be directly extrapolated to human.

Collectively, these data

provide clear evidence of ZSJ-0228’s superior therapeutic efficacy than Dex and
significantly improved safety when compared to Dex and P-Dex[104, 106] in the
treatment of NZB/W F1 mice.

In probing the working mechanism of ZSJ-0228, near-infrared imaging-based
in vivo biodistribution data (Figure 12A) suggests that the prodrug’s main
distribution organ in NZB/W F1 mice was the inflamed kidney. The distribution to
other organs was limited, which is in stark contrast to the observation in human
treated with dexamethasone (with fast extrarenal elimination and high liver
deposition)[148] and in mice with P-Dex (with higher liver and spleen
deposition).[104, 106] Different from P-Dex treatment, ZSJ-0228 treatment has
no impact on splenomegaly (data not shown), which supports the optical imaging
findings. The significantly lower ZSJ-0228 positive cells in other organs counted
by the flow cytometry further validated the nephrotropic distribution pattern of ZSJ0228 (Figure 12B).

Several

promising

nanoformulations

dexamethasone delivery.[149-151]

have

been

developed

for

Comparing to ZSJ-0228, they have the

advantage of significantly reduced cost of manufacture and lower barrier for
regulatory approval. Similar to P-Dex, their biodistribution patterns favor the MPS
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system. We speculate that their relatively higher liver/spleen distribution may be
associated with their high molecular weight or large size.[152] ZSJ-0228, on the
other hand, is considerably smaller (~ 3 kDa). The water-soluble prodrug consists
of a mPEG 1900 and two dexamethasone molecules (Scheme 1). Considering
the hydrodynamic radius of PEG 3000 is around 15 Å,[153] the structurally more
compact ZSJ-0228 should be even smaller than that.

Our ongoing

pharmacokinetic study estimates the t1/2 () of ZSJ-0228 to be around 12 hr, which
is significantly shorter than that of P-Dex.[113, 114] We believe the relatively
smaller size and shorter serum half-life may be the main contributing factor for
ZSJ-0228’s nephrotropicity and low MPS distribution.

Two additional factors may also be considered in understanding ZSJ-0228’s
high distribution to kidney: (1) It has been reported that there is an inverse size
dependency in the renal clearance of sub-nanometer gold nanoclusters (AuNCs),
which is distinctly different from the general understanding that smaller
nanoparticles always clear more rapidly through the kidney than the larger
ones.[154] We postulate that the proposed mechanism of physical retention of
AuNCs by the glycocalyx of the glomeruli may have also helped to slow down the
clearance of ZSJ-0228 from kidney and thus contributed to its high kidney
distribution. (2) According to ELVIS mechanism, inflammatory cells’ accelerated
sequestration is one of the major contributors to the nanomedicine’s high retention
by inflammatory tissues. As shown in Figure 12B, the kidney cells of NZB/W F1
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mice certainly have demonstrated substantially higher sequestration of ZSJ-0228
than the control NZW mice.

It is interesting to note that ZSJ-0228 was also somewhat retained by
kidney/kidney cells of NZW mice (Figures 8 & 9). This is probably due to the
advanced age (> 28 weeks) of the animals being used in this study. NZB/W F1
mice are the offspring of an NZB female (Stock # 000684, Jackson Laboratory)
and an NZW male (Stock # 001058, Jackson Laboratory). Both inbred parental
strains may occasionally develop autoimmune abnormalities that are observed in
the F1, but not necessarily with the same onset or severity. While the NZW mice
have a normal life span, some do develop anti-DNA antibodies, high serum levels
of retroviral gp70 antigen, and nephritis at an advanced age.[137]

Further flow cytometry profiling of kidney cells that internalizes ZSJ-0228
revealed that myeloid cells and proximal tubular epithelial cells were the major
players in sequestration and retention of ZSJ-0228 in the inflamed kidneys of
NZB/W F1 mice (Figure 13). These findings are not surprising as infiltrate myeloid
cells in LN are known to be phagocytic.[155]

It has been reported that

inflammatory insults could reprogram the myeloid cells’ endocytic machinery from
receptor-mediated endocytosis to macropinocytosis,[156] which would accelerate
the rate of cell internalization in a receptor-independent fashion. Proximal tubular
epithelial cells, on the other hand, recycle the albumin via a receptor-mediated
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endocytosis mechanism when exposed to the proteins.[157] One may suggest
the observed endocytosis of ZSJ-0228 (Figures 9-11) by tubular epithelial cells is
a “bystander” effect associated with the cells’ internalization/recycle of albumin.
Due to the potential binding of ZSJ-0228 to albumin,[158, 159] it is also possible
that the prodrug may piggyback albumin and be internalized through the receptormediated endocytic process intended for albumin.

We noticed that while the majority (50%) of renal CD146+ cells (endothelial
cells) internalized ZSJ-0228 (Figure 13B) and IHC analysis suggests a high
CD146+ cellular uptake of the prodrug (Figure 14), the flow cytometry data shows
low prodrug distribution (<1%) to this cell population (Figure 13B).

This

discrepancy may be attributed to the difficulty in isolating endothelial cells from
the kidneys. Typically, a collagenase-based tissue dissociation reagent, Liberase
Blendzyme, can be used to efficiently isolate endothelial cells from tissues. Its
application, however, often results in the damages to other cells.[160-162] Thus,
a gentler cell isolation protocol was used in the present study. We speculate that
this limitation of the current flow cytometry tissue isolation protocol may have
inadvertently lowered the number of endothelial cell population isolated from
kidney and underestimated their contribution to the kidney sequestration of ZSJ0228.
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While ZSJ-0228 demonstrated strong nephrotropicity on the lupus-prone
NZB/W F1 mice, it did not stay in the kidney permanently. The presence of ZSJ0228 in kidney decreased over time (Figures 8 and 9). This is especially true for
the CD11b+ myeloid cells isolated from the kidneys of NZB/W F1 mice. The
percentage of CD326+ cells (proximal tubular epithelium) that internalized ZSJ0228 did not change from day 1 to day 4 post-administration (Figure 13). It has
been reported that GC treatment can induced myeloid cell apoptosis.[163] Renal
epithelial cells, on the other hand, are insensitive to GC treatment.[164] Therefore,
it is possible that the ZSJ-0228 sequestered by myeloid cells may have induced
their apoptosis, leading to the prodrug’s gradual clearance from the kidney. Since
FcR-bearing myeloid cells are responsible for triggering LN,[165] ZSJ-0228’s
specific sequestration by the myeloid cells in kidney may also be a plausible
explanation for ZSJ-0228’s superior efficacy than Dex. Such notion conforms to
the finding shown in Figure 11, where the number of macrophage was significantly
reduced after two months treatment with ZSJ-0228. Clearly, further investigations
are needed to better understand ZSJ-0228’s working mechanism on the cellular
and molecular levels.

The present study does have its limitations. ZSJ-0228 was designed for the
improved efficacy and safety of GC treatment for lupus nephritis, but not for other
lupus complications such as arthritis. Since its main distribution organ is kidney,
ZSJ-0228 may not be effective in managing inflammation at other anatomical sites
of the body. P-Dex17 and other GC nanoformulations,[149-151] which have
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longer serum half-lives may be better suited for these conditions. We speculate
that the development of a GC prodrug that would be effective and safe for most
of the lupus symptoms may necessitate a macromolecular prodrug system that is
conditionally degradable.[166] Regarding administration route, ZSJ-0228 was
given as a monthly i.v. injection in this study. Though the treatment schedule is
favorable, the i.v. route would require healthcare professionals for administration
in clinical setting. Previous work[167] indicates that s.c. and i.p. administrated
polymeric prodrug may enter the circulation through the lymphatic system.
Therefore, we speculate it is possible that ZSJ-0228 may also be given via these
routes and be effective. This approach would enable self-administration of the
medication and further improve the patients’ compliance to the treatment.

3.5 Conclusions

A micelle-forming PEG-based dexamethasone prodrug (ZSJ-0228) was
developed with superior and sustained therapeutic efficacy against nephritis on
lupus-prone female NZB/W F1 mice. No apparent glucocorticoids (GC) side
effects was observed. While as a prodrug of dexamethasone, ZSJ-0228 does not
change the parent drug’s anti-inflammatory and immunosuppressive mechanism
on the molecular level, it indeed alters the pharmacology physiologically by
restricting its distribution to the inflamed kidneys, providing sustained and
localized immunosuppressive and anti-inflammatory effect. We believe ZSJ-0228
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can be further developed into a viable new drug candidate for the better clinical
management of lupus nephritis. We further suggest that this GC prodrug may
also be explored for the clinical management of other renal pathologies, such as
kidney transplant, IgA nephropathy, focal segmental glomerulosclerosis, minimal
change disease and Goodpasture syndrome, in which GCs are frequently used
as first-line therapy.
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CHAPTER IV
PHARMACOKINETIC AND BIODISTRIBUTION STUDY OF PEGBASED DEXAMETHASONE PRODRUG

4.1 Introduction

In the previous chapters, we have fully evaluated the therapeutic efficacy,
adverse effects and potential mechanisms of PEG-based dexamethasone
prodrugs in lupus prone mice. These studies demonstrated that PEG-Dex not
only retains the efficacy but also overcomes the cumulative toxicities of P-Dex as
HPMA is non-biodegradable [104]. Near infrared in vivo imaging showed that
PEG-Dex was highly accumulated in the kidney at 1-day and was retained in the
kidney for at least 4 days, while significantly lower fluorescence-labeled PEG-Dex
signal was detected in the other critical organs including liver. This result was
further validated by a flow cytometry study which showed that approximately 60%
of renal cells internalized PEG-Dex while less than 10% of cells in the other
organs took up the drug. Furthermore, the majority of PEG-Dex was sequestered
by activated myeloid cells and epithelial cells in the kidney.

This in vivo

biodistribution study lasted for only 4 days. However, the therapeutic effects of
PEG-Dex in lupus prone mice appears to last for 1 month as the mice were treated
with PEG-Dex at single dose per month.
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In preliminary studies, both P-Dex and PEG-Dex showed superior efficacy,
compared to dose equivalent free Dex, in the prevention and treatment of lupus
nephritis. While both can overcome the GC-induced skeletal complications, PEGDex micelle was the only one found to be able to avoid WBC count reduction and
adrenal gland atrophy. Our preliminary imaging data suggesting that the two
prodrug nanomedicine’s passive targeting to the kidney may explain their superior
therapeutic efficacy and we postulate that their differential distribution patterns to
the rest of the body and especially the distribution pattern of the Dex released
from the nanomedicine may help explain their different safety profiles. A headto-head comparative PK/BD study is therefore planned to provide insight to PEGDex micelle’s working mechanism.

4.2 Materials and Methods

4.2.1 Materials

The Na

125

I and Dexameshason-d4 were purchased from PerkinElmer

(Waltham, MA). PD-10 column was purchased from GE HealthCare (Piscataway,
NJ). The urine protein level was monitored weekly using Albustix Reagent Strips
(Siemens Healthineers, Erlangen, Germany).

All the organic solvents were
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purchased from Fisher Scientific (Pittsburgh, PA). All compounds used in this
experiment were reagent grade or higher and used without further purification.

4.2.2 Instruments

HPLC analyses were performed on an Agilent 1100 HPLC system (Agilent
Technologies, Inc., Santa Clara, CA) with a reverse phase C18 column (Agilent,
4.6 × 250 mm, 5 μm).

A Packard Cobra II Gamma Counter (PerkinElmer,

Waltham, MA) was used for tissue radioactivity counting in the gamma counterbased PK/BD study. The dexamethasone concentration was measured by LCMS/MS (Agilent Technologies, Inc., Santa Clara, CA).

4.2.3 Synthesis of 125I-Labeled PEG-Dex

The PEG-Dex-Tyr was labeled with 125I using a standard chloramine-T assay.
Na125I solution (basic solution to prevent the evaporation of I 2) and chloramine-T
were dissolved in 0.1N NaOH solution. This solution was stirred at room
temperature for 10 min followed by the addition of the PEG-Dex-Tyr for another
30 min stirring. The reaction was quenched by Na2S2O3, purified over a PD-10
column twice, and the resulting eluate demonstrated strong radioactivity (~1.2
mCi). The entire labeling process was done according to a protocol approved by
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the University of Nebraska Medical Center Radiation Safety Office in a fume hood
with a face velocity of 100 FPM and with lead shield protection. Post-labeling
cleaning and contamination surveys were performed to ensure the absence of
any radiation contamination in the working area.

4.2.3 Animal Experiment

The NZB/W F1 mouse, which is F1 hybrid between the New Zealand Black
(NZB) and New Zealand White (NZW) strains, is a lupus prone strain that was
utilized in this study. Mice were housed under controlled humidity, temperature
and lighting conditions in facilities accredited by the American Association for
Accreditation of Laboratory Animal Care, operating in accordance with standards
set by the Guide for the Care and Use of Laboratory Animals (The National
Academies Press, 1996). All procedures involving live animals were performed in
accordance with protocols evaluated and approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Nebraska Medical Center.

Beginning at 20 weeks of age, NZB/W F1 female mice were monitored
weekly for albuminuria using Albustix. Readings between 1 and 2 (30-99 mg/dL)
are considered ’normal’, whereas readings of ≥2+ (≥100 mg/dL) indicate the
presence of albuminuria. Only the mice in each group with established nephritis,
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evidenced by sustained albuminuria (≥100 mg/dL) for 2 weeks, were officially
included in the study.

A total of 54 mice were used in this experiment. The 125I-labeled and unlabeled
PEG-Dex were mixed and administered to mice (polymer dosage = 5.4 mg/mouse,
~50 g body weight) via tail vein injection. These mice were randomly assigned
into 9 groups containing 6 mice in each group. These groups were sacrificed at 9
different time points (0.5, 2, 4, 6, 24, 72, 168 and 336 h) after injection. Blood and
other major organs were collected at selective time point without perfusion.

4.2.4 Pharmacokinetic and Biodistribution Analysis

Each tissue sample was weighed and counted on the gamma counter to
determine the amount of drug (via radioactivity) in each tissue. After counting,
each tissue sample was homogenized in 3-volumes of H2Oand 100 μL was added
to 1 mL of ethyl acetate to extract free dexamethasone and to remove polymer.
After extraction, the supernatant (900 μL) was withdrawn and transferred to a new
tube with the addition of Internal Standard (IS) solution (10 μL Dexamethasoned4, 1000 ng/mL). The samples were then evaporated, and the residue was
dissolved for LC-MS/MS analysis to determine the free dexamethasone
concentration.
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Spiking solutions in 50% MeOH at different analyte concentrations (1, 2, 5, 10,
20, 50, 100, 200, 500, 1000, 2000, 5000, 10000 ng/mL), a blank and a (zero
analyte + IS) spiking solution were prepared beforehand. Spiking solution (10 μL
each) was added to blank tissue/organ homogenate (100 μL). Then these
standard samples were extracted with 1 mL of Ethyl Acetate. Tthe samples were
evaporated under a vacuum and reconstituted in 100 μL of 50% methanol.
Samples were analyzed using LC-MS/MS to obtain the dexamethasone levels.

The PK/BD analysis includes two parts. One is the PK/BD profile of PEG-Dex
analyzed using gamma counter-based data; and the other is the analysis of free
dexamethasone (Dex) released from PEG-Dex, of which the Dex concentration
was analyzed using LC-MS/MS. The pharmacokinetic parameter, such as
biological half-life (t1/2), the maximum concentration (Cmax) and mean residence
time (MRT) were determined using the bolus intravenous input noncompartmental
analysis WinNonlin (version 6.3, Pharsight, Mountain View, CA). The area under
the curve (AUC) was calculated using the trapezoidal rule.

4.3 Results

4.3.1 Pharmacokinetic profiles of PEG-Dex by Gamma Counter
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The established noncompartmental analytical method was successfully
applied to determine the concentrations of

125

I-labeled PEG-Dex in the major

organs of established lupus nephritis mice. The concentration-time profile of
PEG-Dex after a single i.v. dose of 5.4 mg per mouse is shown in Figure 16. The
reduction of PEG-Dex concentration as a function of time in all the tested organs
was determined.

The concentration of

125

I-labeled PEG-Dex in the kidney

dropped from ~9%/g at 0.5 hour to ~4% ID/g at 2 hour post-injection, and
plateaued. Up to 24 hours after i.v. injection, ~3%ID/g of PEG-Dex still retained
in kidney, which was significantly higher than the concentrations (<1%ID/g) in the
other organs at the same time course. Similarly, the concentration of PEG-Dex
in the organs at different time points were compared (Figure 17) and the levels in
the kidney were dramatically higher than other organs, suggesting that the
majority of PEG-Dex is accumulated in the nephritic kidney in the first 5 time points
(0.5, 2, 4, 6, 24 hour). From 3 day to 28 day, the concentration of PEG-Dex in all
the organs decreased below 0.5 %ID/g, even though the liver showed a higher
level of drug accumulation than other organs during these times.
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Figure 16. The concentration-time profiles of PEG-Dex in blood and major
organs/tissues after a single dose (5.4mg PEG-Dex per mouse) of intravenous
administration (n=5~6, mean ± SD).

Figure 17. Pharmacokinetic profiles of PEG-Dex in blood and major
organs/tissues at selective time points after a single dose (5.4mg PEG-Dex per
mouse) of intravenous administration (n=5-6, mean ± SD).

Pharmacokinetic parameters of the major organs estimated by WinNonlin
were summarized in Table 1, in which AUC is the area under the concentrationtime curve, t1/2 is the biological half-life including alpha phase t1/2() associated
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with distribution and beta phase t1/2() associated with elimination, Cmax is the
maximum concentration, and MRT is mean residence time. The AUC of kidney
is significantly higher than other organs suggesting the highest drug exposure is
found in the kidney. The kidney showed very fast distribution rate (t1/2()=0.48 h)
and slowest clearance rate (t1/2()=31.9 h) amongst other major organs, indicating
the inflamed kidney can be rapidly perfused by PEG-Dex and retain the drug in
the kidney for a longer time after reaching distribution equilibrium. The highest
maximum concentration (Cmax) and mean residence time (MRT) were also
observed in the kidney, which are the additional evidences for the hypothesis that
PEG-Dex can be sequestered mainly by renal tissues and reside in the inflamed
kidney for a longer time compared to the other critical organs.

Table 1. Pharmacokinetic (PK) parameters of PEG-Dex after a single dose of
intravenous administration.
Parameters (unit)

Blood

Kidney

AUC (h·DPM/g)

720622.66 ± 17664.65

2803827.58 ± 500811.86

t1/2() (h)

0.52 ± 0.01

0.48 ± 0.12

t1/2() (h)

11.87 ± 0.49

31.9 ± 7.33

Cmax (DPM/g)

196058.55 ± 2694.12

MRT (h)

14.38 ± 0.63

277785.86 ± 37419.8
43.56 ± 10.3

Parameters (unit)

Liver

Spleen

AUC (h·DPM/g)

1351035.5 ± 213537.15

391741.9 ± 73666.42
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t1/2() (h)

0.99 ± 0.38

0.44 ± 0.19

t1/2() (h)

24.7 ± 5.55

22.73 ± 5.63

Cmax (DPM/g)

76256.39 ± 6294.3

41105.8 ± 9558.24

MRT (h)

33.88 ± 7.57

31.24 ± 7.89

4.3.2 Pharmacokinetic profiles of released dexamethasone by LC/MS.

The weight ratio-time profiles of dexamethasone released from PEG-Dex
prodrugs in major organs (including blood, kidney, heart, liver, spleen and lung)
were shown in Figure 18. In liver, the content of dexamethasone decreases as a
function of time. The Cmax is observed at 2 hours post-injection in liver and is
higher than the other organs suggesting the liver is the major metabolic organ for
PEG-Dex cleaving dexamethasone from PEG-Dex prodrugs.

However, the

elimination phase in kidney is different from liver. In kidney, the content of
dexamethasone reduces slowly in the first 6 hours after injection, and then
reaches a peak with ~120 ng/g dexamethasone at the 24 hour time point,
suggesting a high content of released dexamethasone accumulated in the
inflamed kidney after it was cleaved from PEG-Dex in liver. The similar elimination
phase was observed in the other tested organs but at dramatically lower levels of
the dexamethasone content.

Similarly, when analyzing the dexamethasone

content in major organs at selective time points, a relatively higher accumulation
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of released dexamethasone was observed in the kidney for up to 7 days after
injection, suggesting the controlled release phase of PEG-Dex occurs in the
nephritic kidney.
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Figure 18. The dexamethasone content-time profiles of free dexamethasone
released from the PEG-Dex blood and major organs/tissues after a single dose
(5.4mg PEG-Dex per mouse) of intravenous administration (n=5~6, mean ± SD).

Figure 19. Pharmacokinetics profiles of Dex released from PEG-Dex in blood and
major organs/tissues at each time point post i.v. administration. n=5~6.

4.4 Discussion
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The PEG-Dex was designed to reduce GCs-associated side effects in the
treatment of lupus nephritis through a novel GC prodrug nanomedicine
development. Conceptually, this passive inflammation targeting was based on the
mechanism “ELVIS” which stands for Extravasation through Leaky Vasculature
and Inflammatory cell-mediated Sequestration, in which the nanomedicine would
extravasate through the leaky vasculature at the inflammatory lesion,[13] and its
subsequent inflammatory cell-mediated sequestration would alter the PK/BD
profile of the parent drug, enabling inflammatory tissues/organs specificity.

In this study, we evaluated the pharmacokinetic and biodistribution (PK/BD)
profiles of PEG-Dex in a lupus nephritis mouse model using

125

I-labeling/gamma

counter techniques and LC-MS/MS. The focus of this study was to validate the
preferential distribution of PEG-Dex polymer to inflammatory kidney and its
superior and long-lasting therapeutic effect. As the main activation sites of the
prodrug are probably the organs of its major distribution, the therapeutic effect
and safety profile of the prodrug would be directly related to their PK/BD
profiles.[15]

The pharmacokinetic profiles showed that the concentration of PEG-Dex in
blood decreased rapidly after injection and the beta half-life is only 11.87 hours.
As evident in Figure 16 and Figure 17, a fast distribution and longer retention of
PEG-Dex polymer in kidney comparing to other organs, and the alpha half-life and
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beta half-life are 0.48 hours and 31.9 hours, respectively. Those results proved
that the polymers quickly distributed to kidneys from the blood system after the
systemic injection. The kidney also showed the highest Cmax (277785.86 DPM/g)
and MRT (43.56 hours), which means the kidney was the main organ of drug
distribution. As shown in Figure 17, the majority of PEG-Dex was found in the liver
after 3 days. We speculate this may be due to the liver being the major metabolic
organ of PEG-Dex.

The PK/BD profiles of Dex released from PEG-Dex was presented in Figure
18 and 19. It showed there is a trend toward the slow release trend of PEG-Dex
in the kidney as there were two peaks in the Dex-content vs time curve in kidney
and blood (Figure 18). Also, the kidney showed a greater accumulation of Dex
compared to other organs except the liver, which may explain the superior
therapeutic efficacy of PEG-Dex for treating Lupus nephritis. Due to the Dex
concentration in the liver, which increased at first, peaked at 2 h post injection and
then decreased continuously, we speculate that Dex is mainly metabolized in the
liver.

4.5 Conclusion

In this study, the in vivo pharmacokinetic and biodistribution (PK/BD) profiles
of PEG-Dex were investigated in a lupus nephritis mouse model using

125

I-
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labeling/gamma counter and LC MS/MS. The study found that the PEG-Dex was
preferentially distributed to the kidney and showed a long-lasting therapeutic
effect by constantly releasing Dex. After injection, the PEG-Dex prodrug
distributed to the kidney and reached a steady state within 2 hours, which was the
main organ of the drug distribution. The free dexamethasone was released from
PEG-Dex in the inflamed kidney and its concentration peaked at 24 h, after a
decrease from 0.5 h to 6 h post administration. The findings in this study will assist
in the further design and optimization of PEG-Dex and the understanding of its
nephrotropism.

104

CHAPTER V. SUMMARY AND FUTURE PERSPECTIVES

5.1 SUMMARY

As one of the most severe complications of SLE, lupus nephritis is highly
correlated with lupus patients’ survival and life quality. The pathogenesis of lupus
nephritis involves a complex of pathogenic mechanisms. Although the trigger that
initiates SLE in a genetically susceptible person is still unknown, the etiology of
the widely recognized renal autoantibody can be summarized in two parts, the
extrarenal and intrarenal. The extrarenal etiology involves immune complexes
from circulating blood depositing on the glomerular basement membrane that
triggers a cascade of immune events [23], while intrarenal etiology refers to the
subsequent immune response stimulated by the apoptosis of renal cells injured
by the infiltrated leukocytes migrating from circulating blood [55, 56].

Although the prognosis of proliferative nephritis has been relatively improved
by

glucocorticoids

plus

immunosuppressives

[62],

long-term

use

of

glucocorticoids needs to be cautiously applied due to the various adverse effects
involving multiple systems (i.e. musculoskeletal, endocrine, cardiovascular,
hematopoietic and gastrointestinal systems) [168]. These adverse side effects
dramatically increase the morbidity of lupus patients. According to the most
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recent ACR (American College of Rheumatology) guidance for clinical
management of lupus nephritis [61], the major change is that new
immunosuppressants (e.g. mycophenolate mofetil) have been added as
alternatives to cyclophosphamide. No alternatives have been recommended for
GC.

The actions of GC are mediated through two distinct pathways: transactivation
and transrepression, which are postulated to be related to GC-associated side
effects and anti-inflammatory effects, respectively [169]. GC receptor agonists
can activate the transrepression responses while with low sensitivity and still elicit
GC-associated side effects through triggering the transactivation pathway [132].

Nanomedicine-based drug delivery system seems to be a potential approach
to retain the GC efficacy as well as diminish GC-associated side effects by means
of modifying GC’s PK/BD profiles. In our previous study, we conjugated
dexamethasone to a water-soluble N-(2-hydroxypropyl)-methacrylamide (HPMA)
copolymer via an acid-labile hydrazone linker to obtain a macromolecular prodrug
of Dex (P-Dex). The enhancement of the therapeutic efficacy of P-Dex and
avoidance of osteoporosis were observed, however, a relatively high
accumulation of P-Dex in the liver and other GC-related side effects such as
adrenal gland atrophy and WBC reduction still existed. Herein, to address the
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residual toxicities, we designed a new Dex prodrug using polyethylene glycol
(PEG) as a carrier.

In chapter 2, we conjugated a dexamethasone dimer to PEG chain
terminus via glutamic acid/glycine/hydrazone linker system. The amphiphilic
molecule self-assembles into micelles. The chemical structure of PEG-Dex and
self-assembled micelles were fully characterized. The results demonstrated that
PEG-Dex prodrug was successfully developed. Additionally, critical micellar
concentration (CMC), DLS, and TEM results confirmed the micellar structure.

To evaluate the therapeutic effects of PEG-Dex, pre-clinical treatment
studies were performed on the established lupus nephritis mouse model (chapter
3).

Additionally, the safety profile and the potential mechanism of cellular

interaction with the prodrug were further explored in this part. When tested in
NZB/W F1 mice with established nephritis, the micelle demonstrated similar
potent efficacy as P-Dex, but showed no apparent GC side effects. The potential
reason might be attributed to the modified biodistribution of PEG-Dex in major
organs, for PEG-Dex was passively targeted to the nephritic kidney evidenced by
the in vivo imaging, SPECT-CT and flow cytometry data. Furthermore, we also
found that proximal tubular epithelial is one of the major drug uptaking cells in the
kidney, and in vitro study of human epithelial cell line suggested that the
intracellular lysosome is the primary reservoir for PEG-Dex prodrugs.
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To further address the working mechanism of long-term efficacy of PEGDex in the treatment of lupus nephritis, the pharmacokinetic studies were
performed on mice with established lupus nephritis (chapter 4). In brief, PEGDex was labelled with

125

I and a single dose of PEG-Dex was intravenously

administrated through the tail vein. At selected time points, the major organs were
harvested and their radioactivity representative of the PEG-Dex concentration
was examined by gamma counter. In addition, the released free dexamethasone
from PEG-Dex was extracted from organs and the dexamethasone content was
measured by LC/MS. The pharmacokinetic profiles demonstrated that nephritic
kidney has the highest accumulation of PEG-Dex in the first 24 hours after
injection. The liver may be the major metabolic organ for PEG-Dex as it has the
highest maximum dexamethasone content (Cmax) at 2 hours after injection, while
Cmax was reached much more rapidly. It worth noting that kidney has a cumulative
peak concentration of dexamethasone at the 24 hour time point and maintain a
relatively higher dexamethasone content for up to 7 days. These results further
confirm our hypothesis that PEG-Dex prodrug can passively target to the inflamed
kidney in the condition of lupus nephritis and release the dexamethasone locally
in a controlled release manner.

5.2 Future Perspectives
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At the end of the project, we anticipate being able to identify the final
optimized PEG-Dex micelle formulation that can be further developed for clinical
translation. To achieve this goal, there are a few concepts that should be further
investigated.

1) Optimization of the PEG-based prodrug micelle system. In the current
PEG-based prodrug micelle system, there are a few issues need to be noted. The
hydrazone structure formed at each reaction site has a pair of cis-trans isomers
due to the double bond. As we conjugate a dexamethasone dimer (containing
two dexamethasone molecules, one at each side) to the PEG backbone, even
though we induced TBS to sterically hinder hydrazine bonds forming at one
carbonyl group (C-3), we may still have 4 possible isomers in the final product,
which will make purification complicated and difficult for bulk production.

A

possible solution is to selectively introduce a symmetrical structural linker plus
TBS to theoretically avoid all the isomers. Moreover, the length/MW of PEG
polymers should be further investigated as the cellular interaction with the prodrug
and in vivo PK/BD profiles will be dramatically changed accordingly. Finally,
simpler synthetic routes and repetitive yields need to be further controllable and
stabilized, which is the precondition for the bulky production by the industry.

2) To better guide the structural design for PEG-Dex, the cell-prodrug
interaction mechanism at the molecular level needs to be further explored.
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Whether PEG-Dex enters cells through a receptor-mediated pathway or a nonspecific internalization is still unknown. Some transfected receptor library may be
applied for the receptor screening, which can help determine if there are specific
receptors that will bind with the PEG-Dex moieties. Some other mechanism might
work together to improve the renal internalization of PEG-Dex. It is well known
that PEGylated nanomedicine has a longer half-life in the circulating blood due to
the crown-like structures formed by PEG which can prevent the recognition and
internalization by immune cells. However, very interestingly, a large proportion of
renal cells internalized PEG-Dex in the inflamed kidney, which seems to
contradictto common knowledge about PEG’s property. Recent research has
shown that a possible reason for the avoidance of immune cell internalization
ofPEGlyated nanoparticles is that there are some specific proteins in the
microenvironment which can stop PEG carriers from being internalized by the
cells, i.e., clusterin. Also, researchers reported that the serum level of clusterin in
lupus patients is lower than the healthy people, while a high level of albumin is
detected in the renal inflammation and albumin can increase the drug
internalization. Taken together, an interesting hypothesis is that the lower level of
clusterin and high accumulation of albumin working synergistically to speed up
the renal cells internalization of PEG-Dex prodrugs. However, more research will
be needed to support this hypothesis.

3) Human lupus is a highly heterogeneous disease characterized by
aberrations in multiple immunological processes. Disease heterogeneity is also
110

observed in spontaneous murine models of lupus suggesting that preclinical
studies should encompass a number of different lupus models to more accurately
reflect the complexity of human lupus. Therefore, the original PEG-Dex micelle
will be tested in NZM2410 and MRL/lpr mice to further validate its efficacy and
safety. Additionally, it will also be tested in collagen-induced arthritis (CIA) mice
to validate its potential to ameliorate the arthritis comorbidity of lupus. Based on
the outcome of these experiments and our understanding of the working
mechanism of PEG-Dex micelles, the structure of PEG-Dex will be fine-tuned and
validated in NZB/W F1 mice for its long term (1 year) efficacy and safety in
preparation for clinical application.
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